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Chapter 1. Introduction 
 
 Cereblon (CRBN) is a gene conserved across the animal and plant kingdoms. The 
CRBN family genes encode proteins that contain two conserved domains called the 
ATP-dependent Lon protease-like domain and the thalidomide-binding domain1,2 (also known as 
Cereblon domain of Unknown activity, binding cellular Ligands and Thalidomide (CULT)3). 
CRBN family proteins have been implicated in organismal development4, metabolism5,6 and 
immune system7,8, and its altered functions are linked to defects in neuronal development9 and 
cancer cells survival8,10,11. In this chapter, previous studies reporting functions of CRBN family 
members are summarized. 
 
1.1. Human Cereblon gene was identified as a candidate gene for onset of an intellectual 
disability 
 Human CRBN gene is located on chromosome 3, mapping to 3,148,490-3,179,717 
reverse strand. CRBN was originally identified as a gene associated with onset of an intellectual 
disability (ID), a neurodevelopmental disorder characterized by restricted learning capability 
and adaptive behavior9. A homozygous nonsense mutation within the coding region of CRBN 
gene was found from a large kindred in the U.S. associated with a mild type of non-syndromic 
ID, characterized by IQ scores ranging from 50 to 70 without physical and neuronal anomalies 
or psychiatric disorders9. The mutation forms a putative premature stop codon that leads to 
either expression of a truncated product (418 amino acid long-protein instead of 442 amino acid 
long-wild type protein) or transcript degradation by the nonsense-mediated decay, or both. 
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 Another study implicating a link between CRBN and ID onset was recently reported12. 
The study reported that three independent ID patients associated with behavior anomalies 
shared a common duplicated region of 3p26.3-3p26.2, which contains the complete open 
reading frame of CRBN12. These clinical genetic studies provide evidence that CRBN may play 
a critical role in learning and memory formation. 
 
1.2. The gene's product CRBN contains two evolutionary conserved domains 
 Two transcripts of CRBN gene have been annotated: one encodes a protein that 
contains 442 amino acid residues (isoform 1) and the other encodes a protein that does not 
contain an alanine residue at position 23 of the isoform 1 (isoform 2). Since the isoform 1 has 
been chosen as the canonical protein, it will be referred as the human CRBN protein in the rest 
of the thesis. 
 CRBN protein contains two evolutionary conserved domains: a central 
ATP-dependent Lon protease-like domain (LON domain; spanning residues 76 to 318 of the 
human protein) and a C-terminal thalidomide-binding domain (Thal-BD; spanning residues 319 
to 428)2 (Figure1.1A). 
 The LON domain contains three subregions: two regions whose structures resemble 
to a bacterial LON N-terminal domain and a non-canonical DNA damage-binding protein 1 
(DDB1)-binding motif (spanning residues 188 to 248)1,2 flanked by the regions (Figure 1.1A). 
The DDB1-binding motif forms α-helices that are inserted into the cleft formed by the 
β-propeller A (BPA) and the β-propeller C (BPC) domains of DDB11,2, competing with other 
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interacting proteins such as DDB24 (Figure 1.1B). DDB1-mediated functions of CRBN will be 
discussed later in this chapter. 
 The Thal-BD is composed of 6 antiparallel β-sheets that are positioned away from 
the DDB1 interaction interface1,2 (Figure 1.1B). The domain is responsible for mediating 
interaction with other proteins6,8,10,11. A unique feature of this domain is a hydrophobic pocket 
(formed by W380, W386, W400, F402) that can be occupied by a class of small molecules1,2. 
The presence of the molecules can alter protein interactions, leading to pleiotropic biological 
responses. Details of this feature will also be discussed later in the chapter. 
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Figure 1.1. Human CRBN protein. (A) A scheme representing the domain structure of the 
human CRBN. The N-terminal region, the LON domain, the DDB1-binding motif and the 
Thal-BD are shown in white, cyan, purple and gray, respectively. (B) The structure of the 
human CRBN is shown in ribbon diagram. The regions are shown in respective colors 
corresponding to the scheme. Selected amino acid side chains involved in forming a 
hydrophobic pocket (N351, P352, H378, W380, W386, W400 and F402) are shown as stick 
models. The crystal structure was determined by Chamberlain and colleagues (PDB ID: 4TZ4)2.  
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1.3. CRBN is a substrate receptor of the Cullin4-RING E3 ubiquitin ligase complex 
 In 2010, CRBN was identified as the substrate receptor of the Cullin4-RING E3 
ubiquitin ligase complex4. Functions of the CRBN-containing complex have been described in 
various biological contexts4,6,8,10,13. 
 
1.3.1. The ubiquitin system 
 The ubiquitin system is a major post-translational system conserved in eukaryotes14. 
Ubiquitination, a series of biochemical reactions that covalently attaches a ubiquitin molecule to 
a substrate protein, is performed in combination of 3 enzymes: ubiquitin-activating enzyme (E1), 
ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3). The Figure 1.2 shows a scheme of 
the reactions. First, the C-terminal glycine residue of a ubiquitin molecule is covalently attached 
to a cysteine residue of the E1 in a thiolester linkage in ATP-dependent manner. Second, 
activated ubiquitin molecule is transferred to a cysteine residue of the E2. Finally, E2-E3 
complex facilitates an isopeptide bond formation between C-terminus of the ubiquitin molecule 
and a lysine's ε-amino group of a substrate. Assembly of multiple ubiquitin molecules 
(polyubiquitin chain) linked via their lysine 48 functions as a signal for recognition and 
degradation by the 26S proteasome15. However, non-proteolytic functions of polyubiquitin 
chains via different lysines and monoubiquitination have also been identified in past years16. 
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Figure 1.2. The ubiquitin system. The scheme represents four sequential reactions in general 
ubiquitination. This figure is modified from a figure in the following URL: 
http://docs.abcam.com/pdf/proteins/Ubiquitylation-system.pdf 
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1.3.2. The Cullin4-RING E3 ubiquitin ligases 
 Multi-subunit Cullin-RING E3 ubiquitin ligase complex family is the largest E3 
ubiquitin ligase family present in eukaryotes17. Members of the Cullin family interact with a 
small protein with the RING finger domain (RBX1/2) via a highly conserved region called 
"cullin homology domain" to form a catalytic core17. Seven genes encoding the cullin family 
members have been identified in the mammalian genomes (CUL1, 2, 3, 4A, 4B, 5, 7)18. The 
Cullins have been described in numerous biological contexts, including cell cycle, 
embryogenesis and development18. 
 Like other Cullins, Cullin 4 is widely conserved from yeast to human19. Single genes 
encoding Cullin 4 family proteins are found in S. pombe, C. elegans and Drosophila, two 
closely related paralogs called Cullin 4A and Cullin 4B are present in vertebrates19. Products of 
the two genes are 83% identical, but Cullin 4B contains an additional 149 amino acids-long 
N-terminal region with a nuclear localization signal20. The cul4A and cul4B mice show distinct 
phenotypes21,22, suggesting that their functions in vivo are not entirely redundant. 
 The Cullin 4A/B proteins is a scaffold protein that assembles RBX1 and DDB1 to 
form the core catalytic complex23 (Figure 1.3). Known substrate receptors (called DDB1 and 
Cullin4-associated factors; DCAFs) of the complex, including CRBN (Figure 1.4), interacts 
with the complex via the BPA and BPC domains of DDB14,24. 
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Figure 1.3. The Cullin4-RING E3 ubiquitin ligase complex. The structure of the human 
Cullin4A-RING E3 ubiquitin ligase complex is shown in ribbon diagram. RBX1, Cullin4A, 
DDB1 and the V protein of simian virus 5 (SV5-V) are shown in yellow, orange, green and gray, 
respectively. The crystal structure was determined by Angers and colleagues (PDB ID: 
2HYE)23. 
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Figure 1.4. CRBN interacts with DDB1 to function as a substrate receptor of the CRL4. 
The structure of the human DDB1-CRBN-lenalidomide-Casein kinase1α is shown in ribbon 
diagram. DDB1, DDB1-BM, LON, Thal-BD and Casein kinase 1α is shown in green, purple, 
cyan, gray and magenta, respectively. The crystal structure was determined by Petzold and 
colleagues (PDB ID: 5FQD)25. 
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1.3.3. Endogenous substrates of the CRBN-containing Cullin4-RING E3 ubiquitin ligase 
 Four endogenous substrates of the CRBN-containing Cullin4-RING E3 ubiquitin 
ligase (CRL4CRBN) have been identified: large conductance Ca2+ and voltage-activated K+ 
channels26,27, CLC-1 Cl- channels28, a homeobox protein MEIS21 and glutamine synthetase6. 
 
1.3.3.1. Large conductance Ca2+ and voltage-activated K+ channels 
 Large-conductance Ca2+ and voltage-activated K+ (BKCa) channels are K+-selective 
ion channels activated by either membrane depolarization or altered intracellular Ca2+ 
concentration29. Mammalian BKCa channel is a homotetrameric complex of Slo, the protein 
encoded by a Slowpoke gene family member29. Studies revealed that the CRL4CRBN directly 
targets Slo for ubiquitination, subsequently preventing protein's translocation to the plasma 
membrane, thereby affecting potassium currents upon stimuli26,27. 
 
1.3.3.2. CLC-1 Cl- channels 
 The CLC Cl- channels are responsible for selective flow of Cl- ions across the plasma 
membrane, playing key roles in rest membrane maintenance and electrical excitability 
regulation of cells30. Like Slo, the CRL4CRBN complex ubiquitinates CLC-1, which regulates its 
stability and subcellular localization28. 
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1.3.3.3. MEIS2 
 MEIS2 is a homeodomain transcription factor essential for proper limb formation in 
vertebrates31. Genomic MEIS2 disruptions in human are linked to cardiac septal defects, cleft 
palate and IDs32,33. MEIS2 was identified as an endogenous substrate of the human CRL4CRBN 
by protein microarray analysis1. CRBN binds to MEIS2 via the Thal-BD, and thalidomide or its 
analogs inhibits CRBN-MEIS2 complex formation in mutually exclusive manner1. 
 
1.3.3.4. Glutamine synthetase 
 Glutamine synthetase (GS) produces glutamine through catalyzing the condensation 
of glutamate and ammonia. GS was identified as an endogenous substrate of CRBN through an 
unbiased proteomics approach6. The study showed that upon elevated intracellular glutamine 
level, CRBN targets GS for polyubiquitination and subsequent proteasomal degradation6. The 
study further identified that diacetylation at lysine residues of GS by the histone 
acetyltransferase complex p300-CBP is necessary for the CRL4CRBN mediated degradation6, 
implicating a putative substrate recognition motif for the CRL4CRBN complex. 
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1.3.4. Thalidomide and its analogs alter functions of CRBN 
 CRBN has gained prominence as the direct target of thalidomide and its analogs 
known as immunomodulatory drugs (IMiDs)4,34,35. The presence of these molecules alters 
functions of CRBN, namely antagonizing endogenous substrates in mutually exclusive manner1, 
in parallel enabling CRBN to recruit neomorphic substrates8,10,11,36. 
 
1.3.4.1. Thalidomide and the immunomodulatory drugs 
 Thalidomide (α-(N-phthalimido)glutarimide) (Figure 1.5) first appeared in the 
market in the late 1950s. It was first subscribed as a morning sickness remedy, but its usage was 
banned after its links to congenital anomalies was reported37. Thalidomide came back into focus 
after its therapeutic effects against leprosy38 and some antitumor effects39–41 were identified. At 
present, IMiDs named lenalidomide and pomalidomide (Figure 1.5) have been demonstrated to 
be effective against intractable hematological malignancies including multiple myeloma42 and 
myelodysplastic syndromes with deletion of chromosome 5q43. These drugs have been approved 
for clinical use against multiple myeloma worldwide. 
 
 
Figure 1.5. Thalidomide and the IMiDs. Structures of (S)-thalidomide (left), (S)-lenalidomide 
(middle) and (S)-pomalidomide (right) are shown. 
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1.3.4.2. Identification of CRBN as the primary target of thalidomide 
 For almost half a century, the molecular target of thalidomide remained elusive. By 
using a thalidomide derivative-immobilized resins, Ito and colleagues succeeded to purify 
thalidomide-bound protein complex from human cell lysates, and identified CRBN as the direct 
target of thalidomide4. The group demonstrated that thalidomide modulates ubiquitin ligase 
activity of the CRL4CRBN complex4. The group further showed that CRBN mediates 
thalidomide-induced teratogenicity in zebrafish and chick, which was associated with altered 
expression of the gene encoding fibroblast growth factor 84. This landmark study implicated that 
CRBN may mediate pleiotropic effects of thalidomide and IMiDs. 
 
1.3.4.3. CRBN mediates therapeutic effects of IMiDs against multiple myeloma 
 After identification of CRBN as the primary target of thalidomide, follow-up studies 
revealed that CBRN is also responsible for therapeutic effects of IMiDs, namely by promoting 
cell death in myeloma cells and stimulating interleukin-2 (IL-2) production in T cells34,35. 
 Molecular mechanisms of the IMiDs' therapeutic effects against multiple myelomas 
were unveiled by unbiased screens8,10. Two analyses independently identified that protein levels 
of lymphoid specific transcription factors called Ikaros family zinc-finger protein 1 and 3 (also 
known as Ikaros and Aiolos, respectively) were reduced upon lenalidomide treatment8,10. The 
studies further showed that in the presence of lenalidomide, the CRL4CRBN complex gains 
function to target Ikaros and Aiolos for ubiquitination and proteasomal degradation8,10. 
Reduction of Ikaros and Aiolos was associated with altered transcription of genes encoding 
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interferon regulatory factor 4 (a transcription factor crucial for myelomas' survival) in myeloma 
cells and IL-2 in T cells, in part explaining anti-myeloma and immunomodulatory effect of 
lenalidomide8. 
 
1.3.4.4. CRBN mediates therapeutic effects of lenalidomide against myelodysplastic 
syndrome with deletion of chromosome 5q 
 Lenalidomide is also an effective treatment for myelodysplastic syndrome with 
deletion of chromosome 5q (MDS del(5q))43. A group performed a quantitative analysis to 
investigate changes of proteome and ubiquitome in lenalidomide-treated meyloid leukemia cells 
and identified decreased protein abundance and increased ubiquitination of casein kinase 1α11. 
The group proved that casein kinase 1α is a neomorphic substrate of the CRL4CRBN that is 
targeted for ubiquitination only in the presence of lenalidomide, and its reduction results in cell 
death11.  
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1.3.5. Ubiquitin-independent functions of CRBN 
 Even though many previous studies focused on functions of CRBN in the context of 
the ubiquitin-proteasome system, its ubiquitin-independent functions have started to emerge. 
 
1.3.5.1. CRBN regulates metabolism via interaction with AMP-activated protein kinase 
 AMP-activated protein kinase (AMPK) is a heterotrimeric kinase that functions as 
the master energy sensor by detecting altered ratio of intracellular AMP/ATP and ADP/ATP44. 
Through a yeast two-hybrid screening, the α subunit of AMPK was identified as an interaction 
partner of mammalian CRBN45. The study identified that CRBN suppresses AMPK's activity by 
competing with the γ subunit in mammalian tissue cell culture45. Later, changes in organismal 
metabolism associated with crbn null mice were reported5. The crbn null mice were more 
resistant to high-fat diet than control mice, characterized by less accumulation of fats in the 
epididymal tissues and the liver, improved glucose homeostasis and insulin sensitivity, in part 
due to hyperactivation of hepatic AMPK5. The studies suggest that CRBN may be involved in 
intracellular and organismal energy sensing. 
 
1.3.5.2. CRBN mediates CD147-MCT1 complex maturation 
 Recent publication unveiled non-canonical, chaperone-like function of CRBN46. 
CRBN was identified to interact with a transmembrane glycoprotein CD147 and a 
transmembrane lactate transporter MCT1, promoting maturation and translocation to the plasma 
membrane of the CD147-MCT1 complex46. Either loss of CRBN or lenalidomide treatment led 
21 
 
to destabilization and retention of the complex at the ER46. It was also demonstrated that the 
therapeutic effects of lenalidomide against multiple myeloma and MDS del(5q) as well as their 
teratogenic effects are in part mediated by CD147-MCT1 complex destabilization46. 
 
1.3.5.3. CRBN expression in mitochondria results in enhanced resistance against oxidative 
stress 
 Previous studies have demonstrated that CRBN is widely distributed in the cellular 
compartments, including the cytoplasm4,6, the nucleus1,8,10 and the endoplasmic reticulum26. A 
group identified that transiently expressed CRBN is also partially localized in mitochondria47. 
To specify CRBN's specific functions in mitochondria, the group established a cell line that 
stably expresses CRBN with the mitochondrial-targeting signal (MTS-CRBN)47. MTS-CRBN 
expression resulted in enhanced resistance against oxidative stress associated with reduced 
amount of total carbonylated proteins47. 
 
1.3.5.4. Regulatory functions of CRBN in immune cells 
 Identification of CRBN as the primary target of IMiDs8,10,11 brought focus on its 
functions in immune cells. A recently published paper uncovered a function of CRBN as a 
negative regulator of toll-like receptor 4 (TLR4) signaling pathway7. A group identified that 
transient expression of CRBN reduces NF-κB activity upon lipopolysaccharide (LPS) treatment 
in leukemia monocytic cells7. Tumor necrosis factor receptor associated factor 6 (TRAF6), a 
protein playing the pivotal role in TLR4 signaling pathway, was identified to interact with 
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CRBN7. The presence of CRBN attenuates ubiquitination of TRAF6 and TAB2 (which are 
required for IKK activation), and subsequently suppresses TRAF6 and TAB2-mediated 
activation of NF-κB7. 
 
1.4. Aim of the thesis 
 Even though diverse functions of CRBN have started to emerge, most of the previous 
studies shed light on its neomorphic functions in the presence of IMiDs4,8,10,11,46. Relatively less 
is known about CRBN's functions in the absence of the IMiDs and functions in vivo. This thesis 
aims to investigate IMiDs-independent functions of mammalian CRBN and its invertebrate 
homolog using the fruit fly Drosophila melanogaster. 
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Chapter 2. Human CRBN localizes to aggresome and shows 
cytoprotective effect against proteasomal dysfunction 
 
2.1. Introduction 
 Intellectual disability (ID) is a neurodevelopmental disorder that affects 
approximately 1-3% of the general population48. ID patients are associated with learning and 
adaptive behavior deficits, which restrict them from adapting to the society49. Even though 
socioeconomic burden of ID is significant, measures toward IDs could not be taken for a long 
time mainly due to lack of understanding towards its molecular mechanisms. 
 Links between onset of IDs and mutation and altered gene dosage of CRBN have 
been reported. A homozygous nonsense mutation (R419X) in the coding region of the gene was 
associated with a mild type of ID without morphological and neurological anomalies9. In 
addition, microduplications of the genomic region that includes CRBN were identified from 
unrelated ID patients12. However, its molecular mechanisms are not known. 
 Aggresome is a protein inclusion observed in cultured cells upon stress exposure50. 
Aggresome formation has been considered as an active cell response to sequester the toxic 
misfolded proteins from other organelles and macromolecules51. A series of intracellular 
processes is shown in the Figure 2.151. In brief, regulatory E3 ubiquitin ligases attach Lysine 
63-linked polyubiquitin chains to misfolded proteins when their amount exceeds the capacity of 
the chaperones-mediated folding and the ubiquitin-proteasome system. The polyubiquitinated 
proteins bind to the dynein motor complex via histone deacetylase 6 (HDAC6) and other 
accessory proteins. The protein complex is transferred to the microtubule organizing center, 
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where the aggresome is formed. Once the toxic proteins are concentrated, the aggresomes are 
cleared by bulk autophagy. 
 Some E3 ubiquitin ligases are known as a regulatory factor in aggresome formation. 
Parkin, a RING domain-containing E3 ubiquitin ligase encoded by a familial parkinson's 
disease causing gene52,53, targets substrate proteins for polyubiquitination required for 
transportation to the aggresome54. TRIM50, another RING domain-containing E3 ubiquitin 
ligase, promotes translocation of polyubiquitinated proteins to the aggresome and their 
elimination55. Furthermore, E3 ubiquitin ligases encoded by causal genes of 
neurodevelopmental disorders are recruited to the aggresome upon extracellular stimuli55,56, 
suggesting possible links between the aggresome and onset of the genetic disorders. 
 In this chapter, a role of CRBN in cytoprotection upon proteasome dysfunction is 
described. In the presence of a proteasome inhibitor MG132, CRBN was co-localized with 
aggresome markers at the perinuclear region. The change of its subcellular location was 
inhibited completely by microtubule disruption and partially by IMiD treatment. Transient 
expression of CRBN reduced cell death upon MG132 treatment, whereas its reduction by RNAi 
induction increased cell death, suggesting its role in cytoprotection under altered proteostasis. 
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Figure 2.1. Aggresome formation. The scheme represents four sequential biological processes 
in aggresome formation. 
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2.2. Materials and methods 
2.2.1. Reagents 
MG132 (Peptide Institute), nocodazole (Wako) and (RS)-pomalidomide (Sigma Aldrich) were 
dissolved in dimethyl sulfoxide and stored at -20ºC. 
 
2.2.2. Antibodies 
Following antibodies were used in the experiments mentioned in this chapter: 
Name Source Epitope/Clone Provider 
HA Mouse 16B12 Covance 
HA Rabbit YPYDVPDYA-KLH MBL 
CRBN Rabbit Details not known(1) Abnova 
Ubiquitin Mouse FK2 MBL 
HSP70 Rabbit Details not known(2) Cell Signaling 
γ-tubulin Mouse GTU-88 Sigma Aldrich 
HRP-conjugated secondary Ab - - GE Healthcare 
Fluorophore-cojugated 
sencondary Ab 
- - Life technologies 
(1). The manufacturer describes as "a synthetic peptide of human CRBN". 
(2). The manufacturer describes as "a synthetic peptide corresponding to human HSP70". 
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2.2.3. Molecular cloning 
Human CRBN cDNA clone was obtained from Genome Network Project Human cDNA Clones 
(IRAL038I16, Riken BioResource Center). Coding sequences for full-length CRBN or the 
putative mutant protein associated with the ID (CRBN R419X) were inserted into a mammalian 
expression vector pRK5-HA via SalI and NotI sites. A CRBN shRNA expresion vector was 
generated using the pSilencer Vectors (Life Technologies). A rescue construct that expresses a 
gene encoding wild type CRBN but contains two point mutations to avoid targeting by shRNA 
was generated by using the KOD Plus mutagenesis kit (TOYOBO). The sequences of all 
generated plasmid vectors were confirmed by DNA sequencing. 
 
2.2.4. Cell culture 
Rat adrenal pheochromocytoma PC12 cells were grown in low-glucose Dulbecco's modified 
Eagle's medium (Wako) with 5%(v/v) fetal bovine serum, 5% horse serum and 1% 
penicillin-streptomycin. 
 
2.2.5. Transfection and reagents treatment 
The Lipofectamine 2000 reagent (Life Technologies) was used according to the manufacturer's 
instructions. Cells were cultured in the incubator for 12 to 24 hours after transfection for further 
use. MG132, nocodazole and (RS)-pomalidomide were treated at final concentration of 10μM, 
10μg/mL and 10 or 100μM, respectively. 
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2.2.6. Protein extraction 
Cultured cells were lysed in RIPA buffer (50mM Tris-HCl pH7.5, 150mM NaCl, 1% Nonidet 
P40, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate) with the cOmplete 
Protease Inhibitor Cocktail (Roche). After sonication for further disruption, the lysates were 
centrifuged at 21,500xg for 5 minutes at 4ºC. Supernatants after centrifugation were recovered 
and mixed with 2X sample buffer solution (Wako) and 2-mercaptoethanol (Wako). 
Immunoprecipitation was performed using nProtein A sepharose 4 Fast Flow (GE) and anti-HA 
antibody according to manufacturer's instructions. 
 
2.2.7. Western blotting 
Western blotting was performed based on the standard protocol. In brief, protein samples were 
loaded to sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gels and electrophoresis was 
performed at 150V. Then, proteins were transferred to a methanol-pretreated polyvinylidene 
Difluoride (PVDF) membrane at 100V on ice. 5% nonfat milk solution in TBS-T buffer was 
used for membrane blocking and 2.5% milk solution for antibody incubations. The prepared 
membranes were treated with Novex ECL Chemiluminescent Substrate Reagent (Thermo 
Fisher) or ImmunoStar LD (Wako) to detect the signals. 
 
2.2.8. Immunofluorescent microscopy and image acquisition 
Cells were seeded on 35mm glass based dish (Iwaki). After brief washing step with PBS, cells 
were fixed with 4% paraformaldehyde (Wako) in PBS for 15 minutes at room temperature. 
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Cells were treated with appropriate primary antibody and sencondary antibody. Final samples 
were mounted with VECTASHIELD mounting medium with DAPI (Vector Laboratories). 
Cellular images were acquired by using a confocal microscope FV1000 (Olympus). 
 
2.2.9. Cytotoxicity assay 
To quantify MG132-induced cell death, lactate dehydrogenase (LDH) activity in culture media 
was determined using the Cytotox96 Non-Radioactive Cytotoxicity Assay (Promega) according 
to manufacturer's instructions. 
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2.3. Results 
2.3.1. CRBN is localized at aggresomes under proteasomal inhibition 
 In previous studies, CRBN was reported to localize in the cytoplasm4, the nucleus4, 
mitochondria47 and the ER26. To investigate whether accumulation of misfolded proteins affects 
subcellular localization of CRBN, PC12 cells with transiently expressed HA-tagged human 
CRBN (HA-CRBN) were treated with a proteasome inhibitor MG132. In the absence of MG132, 
HA-CRBN was predominantly expressed in the cytoplasm and the nucleus (Figure 2.2A), as 
reported previously4. After overnight MG132 treatment, on the other hand, HA-CRBN was 
almost exclusively localized at the perinuclear region as a spherical structure in most of the 
HA-CRBN expressing cells (Figure 2.2A). This subcellular localization and structural feature 
were similar to those of aggresomes reported in the previous studies54,57. Therefore, further 
double immunofluorescence studies were performed to compare localization of CRBN with the 
known aggresome markers. Three aggresome markers, γ-tubulin, ubiquitin and Hsp70, all 
co-localized with CRBN in the presence of MG132 (Figure 2.2B-D). Endogenous CRBN also 
co-localized with ubiquitin at the perinuclear region (Figure 2.2E), suggesting that CRBN is 
indeed recruited to the aggresome under accumulation of misfolded proteins and protein 
aggregates. 
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Figure 2.2. CRBN co-localizes with aggresome markers upon MG132 treatment. (A) 
Immunostaining of HA-CRBN in PC12 cells shows that CRBN is localized in the cytoplasm 
and the nucleus (left). HA-CRBN was forming spherical structures (white arrows) at the 
perinuclear region after overnight MG132 treatment (right). (B-D) Co-immunostaining of 
HA-CRBN with γ-tubulin (B), ubiquitin (C) and Hsp70 (D) after overnight MG132 treatment. 
(E) Co-immunostaining of Endogenous CRBN with ubiquitin after overnight MG132 treatment. 
All scale bars represent 10μm. The figures are reprinted from the Figure 1 of Sawamura et al., 
201558. The experiments were performed in collaboration with H. Yamada.  
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2.3.2. A microtubule destabilizer and pomalidomide affects CRBN's localization at 
aggresomes 
 Microtubules are essential in aggresome formation, as ubiquitinated proteins are 
retrogradely transported to the microtubule organizing center by the dynein motor complex and 
accessory proteins51. To confirm whether recruitment of CRBN to the perinuclear region is 
microtubule-dependent, PC12 cells with transiently expressed HA-CRBN were treated with 
nocodazole, a microtubule-distabilizing compound, along with MG132. Nocodazole treatment 
completely abrogated translocation of CRBN to the perinuclear region (Figure 2.3A). This 
result suggests that CRBN is transported to the aggresome in microtubule-dependent manner, 
just like other substrates protein and regulatory proteins of the aggresome formation. 
 Polyubiquitin chain attached to substrate proteins functions as a signal for the 
transportation to the aggresome51. To clarify whether proper E3 ubiquitin ligase activity of 
CRBN is necessary for its translocation to the aggresome, localization of CRBN was confirmed 
in the presence of pomalidomide. In the presence of pomalidomide, translocation of CRBN to 
the aggresome was mildly attenuated, with more CRBN present in the cytoplasm in a diffused 
state (Figure 2.3B). Number of cells with CRBN in the diffused state increased in a 
dose-dependent manner (Figure 2.3C), suggesting that the E3 ubiquitin ligase activity of the 
CRL4CRBN may in part required for the translocation to the aggresome. 
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Figure 2.3. Nocodazole or pomalidomide treatment suppress CRBN's recruitment to the 
aggresome. (A) Immunostaining of HA-CRBN in PC12 cells shows CRBN localized to the 
aggresome after overnight MG132 treatment (white arrows) (left). Nocodazole treatment 
completely abolished the translocation of CRBN to the aggresome (right). (B) Immunostaining 
of HA-CRBN in PC12 cells shows CRBN localized to the aggresome after overnight MG132 
treatment (white arrows) (left). Pomalidomide treatment attenuated the translocation of CRBN 
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to the aggresome, with more diffused state in the cytoplasm (right). (C) Percentage of cells with 
CRBN in the diffused state after pomalidomide treatment was quantified. * indicates P<0.05. P 
values were calculated by Student's t-test. The figures are reprinted from the Figure 2 of 
Sawamura et al., 201558. The experiments were performed in collaboration with H. Yamada. 
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2.3.3. CRBN forms ubiquitin-positive, high-molecular weight aggregates under 
proteasomal inhibition 
 Previous studies have described biochemical features of the aggresome as a 
ubiquitin-positive, high-molecular weight protein complex57. Biochemical analysis was 
performed to confirm whether biochemical features of CRBN change upon proteasome 
dysfunction. Transiently expressed HA-CRBN in PC12 cells was detected as a single band of 
approximately 55-60kDa (theoretical size of CRBN is 51kDa) (Figure 2.4A). The putative 
CRBN mutant associated with the ID (HA-CRBN-R419X) was detected as a single band of 
slightly smaller molecular weight, reflecting the deletion of the C-terminal 24 amino acids 
(Figure 2.4A). Like wild type CRBN, HA-CRBN-R419X was localized to the perinuclear 
region after MG132 treatment (Figure 2.4B), suggesting the loss of the C-terminal region does 
not inhibit recruitment to the aggresome. 
 Next, either HA-CRBN or HA-CRBN-R419X was purified from the MG132 treated 
PC12 cells, and samples with the purified immunocomplex were subsequently subjected to 
western blotting with a ubiquitin-specific antibody. As expected, ubiquitin-positive, 
high-molecular weight HA-CRBN and HA-CRBN-R419X proteins were detected (Figure 2.4C). 
The result further reinforced the previous immunofluorescence data that CRBN is a component 
of the aggresome in the MG132-treated cells. 
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Figure 2.4. CRBN forms ubiquitin-positive, high-molecular weight complexes upon 
MG132 treatment. (A) Total lysates from PC12 cells expressing either wild type (Wild) or the 
ID-associated mutant (R419X) were subjected to western blotting with antibodies against 
indicated proteins. (B) Immunostaining of HA-CRBN-R419X in PC12 cells shows that CRBN 
is localized in the cytoplasm and the nucleus (left). Immunostaining of HA-CRBN-R419X in 
PC12 cells shows that HA-CRBN-R419X was forming spherical structures at the perinuclear 
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region after overnight MG132 treatment (white arrows), just like wild type CRBN (right). (C) 
Either HA-CRBN or HA-CRBN-R419X was immunopurified from MG132 treated PC12 cells 
by immunoprecipitation, and the samples containing immunocomplexes were subjected to 
western blotting with antibodies against indicated proteins. The figures are reprinted from the 
Figure 3 of Sawamura et al., 201558. The experiments were performed in collaboration with H. 
Yamada and K. Matsumoto. 
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2.3.4. CRBN shows cytoprotective effect against proteasomal inhibition 
 Aggresome formation is considered as an active response to protect cells from 
accumulation of toxic misfolded proteins51. To address whether CRBN plays a role in 
cytoprotection against proteasomal dysfunction, the lactate dehydrogenase (LDH) cytotoxicity 
assay was performed to quantify cell death upon MG132 treatment. When either HA-CRBN or 
HA-CRBN R419X was overexpressed, LDH in culture media was significantly reduced (Figure 
2.5A), suggesting that increase of CRBN results in cytoprotective effect against proteasomal 
dysfuntion and subsequent accumulation of toxic proteins. To further confirm the role of CRBN 
in cytoprotection, endogenous CRBN was knocked down by transfecting shRNAi plasmid 
(Figure 2.5B). Reduction of CRBN led to increase of LDH in media, whereas transient 
expression of RNAi-resistant CRBN rescued the increase of LDH (Figure 2.5C). These results 
altogether suggest that CRBN plays a cytoprotective role from misfolded protein-induced cell 
death. 
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Figure 2.5. Transient expression of CRBN enhances cellular resistance against the 
proteasomal dysfunction. (A) LDH release from MG132-treated PC12 cells either expressing 
wild type (Wild) or the ID-associated mutant (R419X) CRBN were quantified. (B) Total lysates 
from PC12 cells expressing either shRNA against CRBN alone or the shRNA with the 
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RNAi-resistant CRBN were subjected to western blotting with antibodies against indicated 
proteins. (C) LDH release from MG132-treated PC12 cells expressing either CRBN shRNA 
alone or CRBN shRNA with the RNAi-resistant CRBN were quantified. The figures are 
reprinted from the Figure 4 of Sawamura et al., 201558. The experiments were performed in 
collaboration with H. Yamada and K. Matsumoto. 
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2.4. Discussion 
 The aggresome is an intracellular protein structure formed when protein loads are 
exceeding the capacity of the protein clearance systems and/or the systems are impaired. To 
sequester the toxic proteins, cells utilize active response mechanism to concentrate the proteins 
to the aggresome and eliminate it by autophagy51. 
 The cellular biological and biochemical data altogether suggested that CRBN is 
recruited to the aggresome upon proteasomal dysfunction. Also, transient expression of 
exogenous CRBN reduced MG132-induced cell death, whereas loss of CRBN enhanced it. As 
environmental factors are the major causal factors for onset of ID, defects in the cytoprotective 
system in neuronal cells due to loss of CRBN may be of importance to ID pathogenesis. 
 From the obtained results, the detailed mechanism of how CRBN protects cells 
against accumulation of toxic proteins cannot be explained. There are at least 3 possible 
explanations: 1. CRBN ubiquitinates misfolded proteins. 2. CRBN functions as an accessory 
protein to promote removal of misfolded proteins from the cytoplasm. 3. CRBN upregulates 
cytoprotective responses related genes to increase cellular capacity to cope with misfolded 
proteins. 
 CRBN is a substrate receptor of the CRL4 complex4, and several substrate proteins 
have been identified1,6,8,10,11,26,28. Therefore a straightforward explanation is that CRBN targets 
misfolded proteins for ubiquitination, like other E3 ubiquitin ligases such as Parkin54 and 
TRIM5055. 
 There were studies showing that CRBN mediates maturation and translocation of 
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proteins either dependent or independent of ubiquitination26,46, implicating that CRBN may play 
roles in intracellular protein trafficking. A previous study identified that an E3 ubiquitin ligase 
named Carboboxy terminus of Hsp70-interacting protein (CHIP) not only ubiquitinates its 
substrate, but also mediates its interaction with HDAC6 to promote proper translocation of 
ubiquitinated proteins to the aggresome59. Thus, CRBN could function in similar manner. 
 Autophagy is a bulk clearance mechanism to eliminate the aggresome. Enhanced 
activity of autophagy ameliorates cytotoxicity induced by mutant huntingtin and other mutant 
proteins associated with neurodegenerative diseases60,61. One major signal cascade that regulates 
activity of autophagy is PI3kinase-PKB/Akt-mammalian Target of rapamycin (mTOR) pathway. 
Of note, FOXO family members, downstream transcription factors of the signal cascade, were 
identified as a regulator of autophagy. Several studies have shown that activated FOXO can 
promote autophagy in at least two distinct mechanisms: regulating indirectly by suppressing 
activity of mTOR62 and regulating directly by inducing expression of autophagy-related 
genes63,64. Since Drosophila homolog of CRBN was identified as a novel regulator of 
insulin-like signaling65 and Drosophila FOXO could be its potential substrate (for details see 
chapter 3), it may be intriguing to investigate whether CRBN regulates protective response 
against accumulation of misfolded proteins via altering functions of FOXO. Further 
investigations, in particular with neuronal cells, will be necessary to elucidate the functions of 
CRBN in this context. 
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Chapter 3. Characterization of Ohgata, the Drosophila ortholog of 
human CRBN 
 
3.1. Introduction 
 Previous studies have reported that loss of function or misexpression of CRBN 
family members causes wide range of phenotypes in vertebrates. In human, a genetic mutation 
or altered gene dosage of CRBN is associated with IDs9,12, implicating that CRBN may play 
roles in neuronal development. In zebrafish, zcrbn inhibition by morpholino antisense 
oligonucleotides leads to morphological defects in limbs and otic vesicles4. Unlike zebrafish, 
morphology of crbn null mice is normal throughout development, instead they are resistant 
against high-fat diet challenge5, implicating that mice CRBN may play roles in organismal 
metabolism at least in the pathological metabolic condition. Mechanistic insights of these 
diverse phenotypes are, however, still lacking. 
 The fruit fly Drosophila melanogaster was chosen to study physiological functions 
of a CRBN family protein. Drosophila is a genetically tractable model organism. With relative 
ease of obtaining genes' mutants and a number of available genetic tools, Drosophila enables to 
study functions of genes and its products in vivo in detail. 
 In this chapter, a function of Ohgata (OHGT), the Drosophila homolog of CRBN, in 
organismal growth regulation is described. A fly line with a strong allele of ohgata (ohgt) gene 
was generated by using an emerging genome editing technology named CRISPR-Cas9 system. 
Phenotypic analyses identified that this mutant allele is associated with overgrowth phenotype 
without changes in the body proportion. Immunofluorescence studies showed that OHGT is 
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expressed in the fat body, an endocrine organ that coordinates nutrient abundance and larval 
growth. Overexpression of shRNA against ohgt in the fat body could phenocopy the overgrowth 
phenotype of the gene's mutant, suggesting that OHGT in the fat body is in part responsible for 
the growth phenotype. Biochemical and gene expression analyses identified that insulin-like 
signaling was elevated in the ohgt mutant, probably due to reduction of genes encoding 
inhibitory cofactors of the circulating insulin-like peptides. Finally, interaction between OHGT 
and Piccolo, the Drosophila homolog of DDB1, was biochemically confirmed, implicating that 
the CRL4CRBN complex may be conserved in Drosophila. 
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3.2. Materials and methods 
3.2.1. Antibodies 
Following antibodies were used in the experiments mentioned in this chapter: 
Name Source Epitope/Clone Provider 
OHGT(1-187) Rabbit GST-OHGT(1-187) Generated in this thesis 
OHGT(15-33) Guinea pig OHGT(15-33)-Cys-KLH Generated in this thesis 
α-spectrin Mouse 3A9 DSHB(1) 
β-tubulin Mouse E7 DSHB 
Lamin Mouse ADL84.12 DSHB 
Human DDB1 Goat C-DLIKVVEELTRIH Abcam 
Ubiquitin Mouse VU-1 Life Sensors 
GFP Chicken Full length GFP Abcam 
HA Rat 3F10 Roche 
Actin Rabbit SGPSIVHRKCF Sigma Aldrich 
Actin Mouse DDDIAALVIDNGSGK Abcam 
Phospho-Akt Rabbit Details not known(2) Cell Signaling 
DILP2 Guinea pig DMKALREYCSVVRN M. Pankratz66 
Horseradish peroxidase-cojugated 
sencondary Ab 
- - Santa Cruz 
fluorophore-cojugated sencondary 
Ab 
- - Life technologies 
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(1). The Developmental Studies Hybridoma Bank, created by the National Institute of Child 
Health and Human Development of the National Institute of Health, and maintained at the 
University of Iowa, Department of Biology. 
(2). The manufacturer describes as "a synthetic phosphopeptide corresponding to residues 
around Ser473 of human Akt protein". 
 
3.2.2. cDNA 
A cDNA clone containing full-length CG3925 ORF (LD28592) was obtained from the 
Drosophila Genomic Resource Center (Biology Department, Indiana University). 
 
3.2.3. Molecular cloning 
Phusion High-fidelity DNA Polymerase, restriction enzymes (EcoRI, SalI and XhoI), antarctic 
phosphatase and T4 DNA ligase were all obtained from NEB. DNA purification after reactions 
was performed using Nucleospin Gel and PCR Clean-up (Macherey Nagel) according to the 
manufacturer's instructions. Transformation was performed using the E. coli DH5α competent 
cells. Plasmid DNA purification was performed using Nucleobond Midiprep kit (Macherey 
Nagel) according to manufacturer's instructions. Purified plasmid DNAs were diluted in 1X 
Tris-EDTA buffer pH8.0 and stored at -20ºC for further use. 
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3.2.4. Generating OHGT-specific antibodies 
Cloning of Glutathione S-transferase-tagged immunogen expression vector 
Coding sequence for amino acid 1 to 187 of OHGT protein was amplified using the primer pair 
shown below (Restriction enzyme sites are underlined and the start/stop codons are shown in 
red): 
F: 5'-ACGCGTCGACATGGACGAAGAGGAGAAC 
R: 5'-TATCTCGAGTCATCGAGGTGGCTGCTGT 
The digested amplicon was inserted into pGEX-4T3 (GE healthcare) via SalI and XhoI sites. 
The insertion of the amplicon into the vector was confirmed by DNA sequencing (Seqlab, 
Göttingen, Germany). The product was named pGEX-OHGT(1-187). 
 
Expression and purification of the recombinant protein 
The E. coli BL21(DE3) competent cells were freshly transformed with the pGEX-OHGT1-187. A 
bacterial colony was picked up and was grown overnight in 25mL LB media with Ampicillin to 
a final concentration of 100μg/mL at 37ºC. The next day, fresh LB media was added up to 1L 
and further incubated for 1.5 hours at 30ºC. The isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was added to a final concentration of 0.1mM to induce recombinant protein expression, and the 
culture media was further incubated for 3 hours at 30ºC. 
The bacterial media were centrifuged at 4,000xg for 10 minutes at 4ºC. The cell pellete was 
resuspended with 50mL glutathione S-transferase (GST)-binding buffer (25mM Tris-HCl pH7.5, 
150mM NaCl, 1mM EDTA and the cOmplete Protease Inhibitor Cocktail (Roche)). To lyse the 
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cells, lysozyme was added to a concentration of 10μg/mL and the mixture was incubated for 30 
minutes on ice. After adding glycerol and Triton X-100 to respective final concentrations of 
10% and 0.5%, the mixture was sonicated for further cell disruption. The lysate was centrifuged 
at 15,000xg for 10 minutes at 4ºC, and the soluble fraction was collected and pooled for 
purification of the GST-tagged OHGT(1-187) (GST-OHGT(1-187)). 
Dithiothreitol was added to the soluble fraction to a final concentration of 1mM. 50% slurry of 
prewashed glutathione sepharose 4B (GE healthcare) was added, and the mixture was incubated 
for 2 hours at 4ºC. The beads were collected by centrifugation at 500xg for 2 minutes. After 
supernatant was removed, the beads were washed 4 times with 1% PTX buffer (1% Trition 
X-100 in 1X PBS), 4 times with 1X PBS and once with the GST-binding buffer. After 
supernatant was removed, the washed beads were incubated in elution buffer (10mM reduced 
glutathione in 50mM Tris-HCl pH8.0) for 15 minutes at room temperature. The supernatant that 
contains the recombinant protein was recovered. Fraction at each process was collected to 
confirm the protein abundance by SDS-PAGE gel electrophoresis. 
 
Immunization 
Stability of purified GST-OHGT(1-187) was confirmed by incubating it overnight at 37ºC. Then 
the protein solution was sent to Pineda antibody service (Berlin) for injection into rabbits. A 
synthetic polypeptide corresponding to amino acid 15 to 33 of OHGT with a cysteine residue at 
the C-terminus (RDEDVQLEDQQSQGLQDRQC; referred to as OHGT(15-33)-Cys) was 
covalently immobilized to the Keyhole Limpet Hemocyanin (KLH), and the protein complex 
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was injected into guinea pigs. Sera were collected from the immunized animals at 150 days post 
immunization. 
 
Affinity purification 
To prepare an affinity column for anti-OHGT(1-187) purification, GST-OHGT(1-187)-attached 
glutathione sepharose 4B was incubated in thrombin solution (1U/20μL of thrombin (GE 
healthcare) in 1X PBS) for overnight at room temperature with constant rotation. On the 
following day, thrombin digest flow-through, which contains cleaved OHGT(1-187) and 
thrombin, was directly transferred to a column containing prewashed benzamidine sepharose 4 
fast flow (GE healthcare). The capped column was incubated for 30 minutes at room 
temperature. The flow-through from the benzamidine column, which contains cleaved 
OHGT(1-187), was dialyzed using Slide-A-Lyzer G2 Dialysis Cassette (Thermo Fisher) 
according to manufacturer's instructions. The purified OHGT(1-187) recombinant peptide was 
immobilized to CNBr-activated sepharose 4B (GE healthcare) according to manufacturer's 
instructions. 
To prepare an affinity column for anti-OHGT(15-33) purification, the OHGT(15-33)-Cys 
peptide was immobilized to the Sulfolink Coupling Resin (Thermo Fisher) according to 
manufacturer's instructions. 
The prepared columns were stored at 4ºC with 0.02% sodium azide in 1X PBS. 
To purify IgGs, 2mL antisera were mixed with 2mL PBS, and the mixture was loaded to the 
corresponding column. The column with antisera solution was incubated for 2 hours at room 
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temperature with constant rotation. The column was subsequently washed 3 times with 4mL 
PBS. The bound proteins were eluted with 500μL 100mM Glycine-HCl pH2.8, and then the 
eluate was neutralized with 100μL 1M Tris-HCl pH 8.8. 5 fractions were prepared in total. Each 
fraction was subjected to SDS-PAGE gel electrophoresis to confirm the presence of IgGs. The 
fraction with the largest amount of IgGs was stored at 4ºC for further use. 
 
Antibody validation 
Biochemical analysis was performed to validate OHGT-specific antibodies' specificity. Early 
3rd instar larvae of following genotypes were collected: w* (as a control), homozygous ohgtEx2 
and transheterozygous ohgtEx2/ohgtDf. The same number of larvae (5-15) were lysed in RIPA 
buffer containing the cOmplete protease inhibitor cocktail (10μL/larva). Sample preparation and 
western blotting were performed as described later in this section. 
 
3.2.5. Fly works 
All flies were maintained in standard stock food (11.3L distilled water, 90g agarose, 165g yeast 
powder, 615g cornmeal, 1L syrup, 200mL 10% methylparaben solution) at 18ºC or 25ºC.  
All crosses were performed in the small embryo collection cages. Embryos were collected on an 
apple agar plate with yeast paste for 4 hours if there is no further indication. 
To represent genotypes, semicolon separates chromosomes (unaffected chromosomes are 
omitted), slash separates different alleles of the same chromosome, plus sign indicates wild type 
chromosomes, and comma separates different constructs and alleles on the same chromosome.  
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Name (genotype) Description Provider 
w* (w* ; ;) Control Bloomington #5905 
ohgtEx2 (w1118 ; ; ohgtEx2) ohgt mutant allele Generated in this thesis 
ohgtDf (w1118 ; ; Df(3R)Exel6155, 
P{XP-U}Exel6155/TM6B, Tb1) 
A deficiency line deleting the region 
containing ohgt locus 
Bloomington #7634 
UAS-ohgtRNAiv40486 (w1118 ; ; P{GD11111}v40486) ohgt RNAi line VDRC(1) #40486 
UAS-ohgtRNAiNIG3 (w1118 ; ; P{NIG.3925R}) ohgt RNAi line NIG(2) #3925R-3 
UAS-dDDB1RNAi (w* ; P{UAS-dDDB1.650-dsRNA}23) pic RNAi line Kyoto(3) #109605 
UAS-dCullin4RNAi (w1118 ; ; P{GD14006}v44829) dCullin4 RNAi line VDRC #44829 
UAS-GFP.nls (w1118 ; P{w[+mC]=UAS-GFP.nls}14) Induces expression of GFP  Bloomington #4775 
Cg-Gal4 (w1118 ; P{Cg-Gal4.A}2) Expresses GAL4 in the fat body and 
hemocytes 
Bloomington #7011 
FB-Gal4 (w* ; P{w+mW.hs=GawB}FB/SNS) Expresses GAL4 in the fat body Kühnlein lab(4) 
Dilp2-Gal4 (w* ; Dilp2-Gal4/Cyo, twi-GFP) Expresses GAL4 in the 
Insulin-producing cells (IPCs) 
Bloomington #37516 
hs-FLP CD2GFP (y, hs-FLP ; Dicer2 ; 
act-FRT-CD2-FRT-Gal4, UAS-GFP/TM6b, Tb, Hu) 
For performing clonal analysis Hoch lab(5) 
vas-Cas9 (y1, w1118, M{vas-Cas9}ZH-2A/ FM7c) For performing CRISPR-Cas9 
targeted mutagenesis 
Bloomington #51323 
DrMio/TM3-GFP Sb1 Ser1 (w1118 ; ; DrMio/TM3, 
P{GAL4-twi.G}2.3, P{UAS-2xEGFP}AH2.3, Sb1, Ser1) 
For isolating dCRBNEx2 Bloomington #6663 
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(1). Vienna Drosophila Resource Center 
(2). National Institute of Genetics 
(3). Drosophila Genomics and Genetic Resources (Kyoto Stock Center) 
(4). A line described in Grönke et al., 200367 
(5). The line was established using a line described in Pignoni and Zipursky, 199768 
 
3.2.6. Generating an ohgata mutant alleles using the CRISPR-Cas9 genome editing 
technology 
CRISPR-Cas9-mediated mutagenesis and its screening were performed based on the protocols 
described in the previous studies69–71. 
Designing Cas9 target sites 
The CRISPR Optimal Target Finder (tools.flycrispr.molbio.wisc.edu/targetFinder) was used to 
search for potential target sites within the ohgt locus. Since the two evolutionary conserved 
domains, the LON domain and the Thal-BD, are encoded by exon 3 to 5, genomic sequence 
containing exon 1, exon 2 and an intron between the exons was used as an input. Following 
parameters were chosen to look for potential target sites: 
1. Length of target site: 20bp 
2. Single G at the 5' end (for the efficient transcription from the U6 promoter) 
3. Stringency: High 
4. PAM: NGG only 
From 11 candidates, a sense sequence within exon 2 was chosen as the target site (Figure 3.6). 
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Cloning guide RNA expression vectors 
The molecular cloning of guide RNA expression vectors was performed according to the 
previous study70. In brief, following oligonucleotides were obtained (underlined sequences are 
complimentary to overhangs generated by BbsI digestion): 
F: 5'-CTTCGCAGGACGACACAGCAAGCG 
R: 5'-AAACCGCTTGCTGTGTCGTCCTGC 
1μmole of each oligonucleotide was used for annealing. After 5'-phosphorylation by using T4 
polynucleotide kinase (NEB), oligonucleotides were annealed by following thermal cycler 
program: 95ºC for 5 minutes, subsequently ramp to 25ºC at the rate of -0.1ºC/sec. The 
5'-phosphorylated, annealed oligonucleotides were then inserted into digested 
pU6-BbsI-chiRNA plasmid vector via BbsI site. The sequences of cloned plasmids were 
confirmed by DNA sequencing (Seqlab, Göttingen, Germany). The cloned plasmid guide RNA 
expression vector was named pU6-ohgtEx2-gRNA. 
 
Screening by High resolution melt analysis and molecular characterization 
The Figure 3.7A shows a workflow to isolate an ohgt mutant allele. High resolution melt 
analysis (HRMA) was chosen as a method to screen mutation holders from candidates. HRMA 
is a simple, rapid and sensitive method for genotyping that utilizes different melting profiles 
among double stranded DNA fragments72. In brief, PCR is performed using genomic DNAs 
derived from mutant candidates and a primer pair franking the mutation site. Melt curves of the 
amplicons are obtained through repetitive denaturing and reannealing processes. Presence of 
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mutations within the amplicon results in heteroduplexes formation, resulting in different melting 
profiles from wildtypic homoduplexes. 
A primer pair was designed based on the following parameters72: 
1. Size of the amplicons should be 90-120bp long. 
2. The mutation site should locate more than 20bp away from both ends. 
3. The annealing temperature should be in the range of 59-61ºC. 
Based on the parameters, following primer pairs were designed and obtained: 
F: 5'-ATGCCTTCCAAGATCCACTG 
R: 5'-TGTCACTGCTGGGATGACTG 
Efficiency of the primer pair was confirmed with genomic DNAs derived from the flies carrying 
a GFP-balancer chromosome (DrMio/TM3-GFP Sb1 Ser1; considered as the control in this 
experiment) prior to use. 
The guide RNA expression vectors were injected into vasa-Cas9 preblastoderm embryos at 
250ng/μL. The embryo microinjection was performed according to the standard protocol. On 
the next day after injection, hatched larvae were collected and raised on standard stock food at 
25ºC until eclosion. The eclosed flies were collected and were independently crossed with the 
flies carrying a GFP-balancer chromosome. After 5-7 days, the injected animals were sacrificed 
and homogenized in the squishing buffer (10mM Tris-HCl pH8.2, 1mM EDTA, 25mM NaCl 
and 1X proteinase K) to obtain their genomic DNAs. HRMA was performed using Precision 
Melt Supermix reagent (Biorad) according to manufacturer's instructions. F1 progenies from 
modification-positive parents were further raised until eclosion, and the latter processes were 
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repeated in the F1 generation to assess germline transmission of the targeted modification. 
Amplicons showing different melt profiles from the control were purified after the agarose gel 
electrophoresis, and they were inserted into pCRII-TOPO vector (Thermo Fisher) for DNA 
sequencing. 
 
3.2.7. Phenotypic analyses 
To quantify average weight of adult flies, 10 staged animals were pooled in a 1.5mL eppendorf 
tube and weighed. To quantify pupal length and adult wing area, pupae or wings of indicated 
genotypes were aligned on apple agar plates or glass plates, and their images were obtained 
using the Olympus SZ12 binocular and the SIS Analysis 2.1 software. Their length or area was 
quantified using the ImageJ (National Institute of Health). To quantify cell numbers in the 
posterior compartment of the wing, numbers of hairs in 10,000μm2 were counted, since each 
hair is produced from a single epithelial cell. Number of cells in the compartment was 
calculated by multiplying the area of the compartment with the cell density (cell number/μm2). 
 
3.2.8. Developmental timing assay 
Embryos of indicated genotypes were collected within 2 hours. After 24 hours, 100 larvae were 
transferred to fresh apple agar plates with yeast paste (25 larvae per plate). Number of pupae on 
each plate was counted every 12 hours. Pupariation timing was defined as the time point which 
more than half of final number of pupae had pupated73. 
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3.2.9. Immunohistochemistry and image acquisition 
Larvae were raised on an apple agar plate with yeast paste until indicated timing. Washed and 
dissected larvae were fixed with 4% paraformaldehyde/PBS for 40 minutes at room temperature. 
The fixed samples were blocked in the PTX buffer (0.3% Triton X-100 in 1X PBS) containing 
2% donkey serum (D.S.) for 30 minutes at room temperature. Blocked samples were later 
incubated in the appropriate primary and secondary antibody solutions (antibody solution in the 
PTX buffer containing 2% D.S.). The final samples were mounted on glass plates with the 
Fluoromount-G (SouthernBiotech). The confocal microscope LSM710 (Carl Zeiss) was used for 
images acquisition. 
 
3.2.10. Clonal analysis 
Virgin females of the hs-FLP CD2GFP and males of the UAS-ohgtRNAiv40486 were crossed to 
obtain progenies with following genotype: y, hs-FLP/+; Dicer2/+; act-FRT-CD2-FRT-Gal4, 
UAS-GFP/ UAS-ohgtRNAiv40486. At the indicated timing, the larvae were collected and dissected 
to prepare immunohistochemical samples as described previously. 
 
3.2.11. Protein extraction 
RIPA buffer (50mM Tris-HCl pH7.5, 150mM NaCl, 1% IGEPAL CA-630 (Sigma), 0.5% 
Sodium deoxycholate, 0.1% SDS) with the cOmplete protease inhibitor cocktails was used for 
protein extraction unless otherwise mentioned. Prewashed Animals were homogenized in 
ice-cold RIPA buffer with plastic pestles. Supernatants after centrifugation were transferred to 
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new eppendorf tubes and were mixed with 5X Laemmli buffer with 10% 2-mercaptoethanol. 
The mixtures were subsequently heated at 95ºC for 7 minutes to denature proteins. 
 
3.2.12. Western blotting 
Western blotting was performed based on the standard protocol, as described in the chapter 2. 
After the final washing step, the PVDF membranes were treated with the Pierce ECL Western 
Blotting Substrate or the SuperSignal West Femto Maximum Sensitivity Substrate (both 
Thermo Fisher) for blotting using the CURIX 60 (AGFA healthcare). 
 
3.2.13. Generating tagged OHGT expression vectors 
Coding sequence for full length OHGT with a HA tag at the N-terminus was amplified with the 
following primer pair (restriction enzyme sites are underlined, the start/stop codons are shown 
in red): 
F: 5'-GGAATTCATGTACCCATACGACGTCCCAGACTACGCTGACGAAGAGGAGAAC 
R: 5'-CCGCTCGAGTCATTCCATATCGCTTGAGATC 
The digested amplicon was inserted into pUASTattB vector via EcoRI and XhoI sites. The 
generated plasmid vector was named pUASTattB-HA-OHGT. 
 
3.2.14. Cell culture and transfection 
Drosophila Schneider 2 cells (S2 cells) were raised at 25ºC in the Schneider's Drosophila 
medium (Thermo Fisher) containing 10% fetal bovine serum and 1% penicillin-streptomycin. 
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The Effectene Transfection Reagent (Qiagen) was used for transient transfection of S2 cells. 
Transfection was performed according to the manufacturer's instructions. The 
pUASTattB-HA-OHGT was co-transfected with pAct-Gal4 vector to induce expression. 
 
3.2.15. Fractionation of S2 cells 
Subcellular fractionation of S2 cells was performed using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Fisher) according to the manufacturer's instructions. 
Protein concentration of each fraction was quantified using the Pierce BCA Protein Assay Kit 
(Thermo Fischer). 
 
3.2.16. Co-immunoprecipitation 
S2 Cells were pelleted and lysed in ice-cold lysis buffer (50mM Tris-HCl pH8.0, 150mM NaCl, 
1% IGEPAL CA-630 with the cOmplete protease inhibitor cocktail) by incubating on ice for 15 
minutes. The cells were further disrupted using a 20G needle. The lysates were centrifuged at 
12,000xg for 10 minutes at 4ºC and supernatants were transferred to new eppendorf tubes. 
Co-IP was performed using the Protein G sepharose 4 Fast Flow (GE healthcare) according to 
the manufacturer's instructions. 
 
3.2.17. In vivo ubiquitination 
S2 cells were treated with MG132 for overnight at final concetration of 25μM. The cells were 
pelleted and lysed in the harsh lysis buffer (50mM Tris-HCl pH8.0, 150mM NaCl, 1% SDS, 
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1mM DTT and the cOmplete protease inhibitor cocktail). After vigorous vortex and sonication, 
the cell lysates were incubated for 30 minutes at 4ºC with constant rotation. After centrifugation 
at 12,000xg for 10 minutes at 4ºC, diluting buffer (50mM Tris-HCl pH8.0, 150mM NaCl) was 
added to supernatants to dilute SDS. OHGT immunoprecipitation was performed using the 
Protein G sepharose 4 Fast Flow and anti-OHGT(1-187) according to the manufacturer's 
instructions. 
 
3.2.18. mRNA extraction 
Approximately 10 animals were used for total mRNA extraction and 15-20 animals for tissue 
specific mRNA extraction, respectively. mRNA extraction was performed using the Nucleospin 
RNA kit (Macherey-Nagel). Animals were pooled in screw cap microcentrifuge tubes and were 
snap frozen by using liquid nitrogen. The animals were homogenized using the Precellys 24 
Lysis and Homogenization System (Bertin) in lysis buffer RA1 containing 2-mercaptoethanol. 
The latter processes were performed according to the manufacturer's instructions. After elution, 
mRNA concentration was measured and the solution was stored at -80ºC for further use. 
 
3.2.19. cDNA synthesis 
QuantiTect Reverse Transcription Kit (Qiagen) was used to digest genomic DNA and to 
synthesize cDNA. 500ng of the extracted mRNAs was used as templates. The reaction mix was 
diluted into 5X with distilled water to perform quantitave Real-time PCR (qRT-PCR). 
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3.2.20. Quantitative Real-time PCR 
qRT-PCR was performed using the iQTM SYBR® Green Supermix and the iQ5 Real-Time PCR 
detection system (both Biorad) according to the manufacturer's instructions. Each reaction mix 
was loaded in triplicate, and the average CT value was used to calculate the expression levels of 
genes of target via the -2ΔΔCT method. The gene encoding Ribosomal protein L32 (rp49) was 
used as a reference gene.Following primer pairs were used in the experiment: 
Gene nameReference number Primer pairs 
ohgata (ohgt)65 F: 5'-AAGATGCCTTCCAAGATCCAC 
R: 5'-TCGCTTGCTGTGTCGTC 
Insulin-like receptor (dInR)74 F: 5'-AACAGTGGCGGATTCGGTT 
R: 5'-TACTCGGAGCATTGGAGGCAT 
Thor (d4EBP)74 F: 5'-CATGCAGCAACTGCCAAATC 
R: 5'-CCGAGAGAACAAACAAGGTGG 
Lipase 3 (Lip3)74 F: 5'-TGAGTACGGCAGCTACTTCCCT 
R: 5'-TCAACTTGCGGACATCGCT 
Acid-labile subunit (dALS)75 F: 5'-ATGCGGTGGCTGTCATGTC 
R: 5'-GGCAGCTTACCAAAGGCACTT  
Imp-L2 (Imp-L2)76 F: 5'-AAGAGCCGTGGACCTGGTA 
R: 5'-TTGGTGAACTTGAGCCAGTCG 
Unpaired2 (upd2)77 F: 5'-CGGAACATCACGATGAGCGAAT 
R: 5'-TCGGCAGGAACTTGTACTCG 
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Ribosomal protein 49 (Rp49)74 F: 5'-GCTAAGCTGTCGCACAAATG 
R: 5'-GTTCGATCCGTAACCGATGT 
 
3.2.21. In silico analyses 
SWISS-MODEL service78 (https://swissmodel.expasy.org/) was used to create the 
OHGT-Piccolo complex 3D model using the human CRBN-DDB1 complex as the template 
(PDB 4TZ42). UCSF Chimera79 (a molecular graphics program developed by the Resource for 
Biocomputing, Visualization, and Informatics at the University of California, San Francisco 
(supported by NIGMS P41-GM103311)) was used to reposition the created model to the 4TZ4 
model and for image acquisition. 
The phylogenetic analysis of CRBN family members was carried out by Bayesian inference 
(Markov chain Monte Carlo method, Jones amino acid model) using MrBayes80–82. Analysis 
was carried out for eight chains until they converged (average standard deviation of split 
frequencies: 0.004868; potential scale reduction factor: 1.000; average effective sample size: 
2432.32). 
Following in silico tools were used to predict possible post-translational modification sites and 
sequence motifs: Expasy Scan Prosite tool83,84 (to predict myristoylation sites, phosphorylation 
sites and motifs; http://prosite.expasy.org/scanprosite/); iUbiq-Lys85,86 (to predict lysine 
ubiquitination sites; http://www.jci-bioinfo.cn/iUbiq-Lys); GPS-SUMO87,88 (to predict lysine 
sumoylation sites and SUMO-interaction motifs; http://sumosp.biocuckoo.org/); PSORT II 
Prediction (to predict subcellular localization; http://psort.hgc.jp/form2.html); NucPred89 (to 
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predict nuclear localization of a protein; http://www.sbc.su.se/~maccallr/nucpred/). The latter 
two programs predict subcellular localization of a protein based on the percentage of basic 
amino acids and similarity to other known nuclear proteins. 
 
3.2.22. Statistics 
Mann-Whitney U test was performed to calculate p values for (C) to (F) of the Figure 3.11. 
Student's t test was performed to calculate p values for other experiments. * indicates p<0.05, 
and ** indicates p<0.01. 
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3.3. Results 
3.3.1. The Drosophila CG3925 gene encodes the putative CRBN family member 
 CRBN homologs are evolutionary conserved from vertebrates to invertebrates as 
indicated by phylogenetic analysis (Figure 3.1A). Most proteins are relatively distant from each 
other, as mammalian proteins seem to have split off early and large set of modification between 
the protein of C. elegans and those of insects exist. Even within the insects, the Drosophila 
proteins are remote from those of other insect species. In particular, N-terminal regions of the 
proteins differ greatly, suggesting that their functions may differ to some extent. 
 According to the Flybase, a database of Drosophila Genes and Genomes 
(http://flybase.org/), there is a single annotated homolog of human CRBN named CG3925 in 
Drosophila genome. CG3925 is located on 85F8, chromosome 3R (10,049,199 to 10,051,527). 
The gene consists of five exons, which encompasses approximately 2.3kbp (Figure 3.1B). An 
annotated transcript is expected to encode a putative protein (CG3925-PA) consisting of 585 
amino acid residues with a theoretical molecular weight of 66.5kDa. 
 Protein Sequences alignment by using the Protein Basic Local Alignment Search 
Tool (Protein BLAST) identified that the two functional domains (a central LON domain and a 
C-terminal Thal-BD) may be conserved in CG3925-PA (Figure 3.1C; amino acid residues 234 
to 414 show 24% identity, and amino acid residues 453 to 555 show 44% identity to 
corresponding regions in human CRBN, respectively), whereas the N-terminal region show no 
identity. Further analysis using in silico tools identified potential post-translational modification 
sites for phosphorylation, ubiquitination, myristoylation and sumoylation (Figure 3.1D). 
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Figure 3.1. The Drosophila CG3925 gene encodes a putative CRBN homolog.  
(A) Phylogenetic tree of CRBN family proteins. Depicted values indicate posterior probabilities. 
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The scale bar represents branch length. (B) A scheme representing CG3925 gene locus. Exons 
and untranslated regions are indicated as filled boxes (light gray and dark gray, respectively). 
The scale bar represents 1kbp. (C) Schemes representing human CRBN and its Drosophila 
homolog CG3925-PA. The LON domain, the DDB1-binding motif and the Thalidomide-binding 
domain are indicated as filled boxes (cyan, purple and light gray, respectively). Amino acid 
identities of the corresponding regions are noted. (D) A scheme representing potential 
post-translational modification sites identified by in silico tools. Following post-translational 
modification sites and a motif is shown in the figure: a SUMO interaction site (aa34-38); 5 
myristoylation sites (aa87-92; 136-141; 206-211; 259-264; 549-544); a cAMP and 
GMP-dependent protein kinase phosphorylation site (aa160-163); a ubuiquitination site (K315); 
a sumoylation site (K488); a proline-rich region (aa177-189). A region resembling part of the 
atrial natriueretic peptide (aa161-192) and a C. elegans Her-1-like stretch (aa440-459) were also 
predicted (not shown in the figure). The figures are reprinted from the Figure 1B and the Figure 
2A of Wakabayashi et al., 201665. The phylogenetic tree was generated in collaboration with A. 
Voelzmann. 
 
  
66 
 
3.3.2. Generating antibodies against Drosophila CRBN 
 In order to generate CG3925-PA-specific antibodies, two immunogens were designed 
(Figure 3.2). One immunogen consists of an N-terminal fragment of the CG3925-PA (amino 
acid residues 1 to 187) and a GST tag at the N-terminus (referred to as GST-OHGT(1-187)) 
expressed and purified from BL21(DE3) E. coli (Figure 3.3). Another immunogen is a synthetic 
polypeptide consists of amino acid residues 15 to 33 of the CG3925-PA with KLH protein 
covalently attached to the C-terminus via a cysteine residue (referred to as 
OHGT(15-33)-Cys-KLH). 
 Polyclonal antibodies were affinity purified from antisera using the prepared affinity 
columns. IgGs were successfully purified from both rabbit and guinea pig antisera (Figure 3.4). 
Specificity of the affinity purified-antibodies was confirmed by western blotting using mutant 
flies generated by targeted mutagenesis (see Figure 3.7E,F). 
  
67 
 
 
Figure 3.2. Designing immunogens. To generate CG3925-PA-specific antibodies, two 
immunogens were designed as represented. GST: Glutathione S-transferase; OHGT(1-187): 
amino acid residues 1 to 187 of CG3925-PA; OHGT(15-33): amino acid residues 15 to 33 of 
CG3925-PA; KLH: Keyhole Limpet Hemocyanin. The figures are reprinted from the Figure 1B 
of Wakabayashi et al., 201665. 
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Figure 3.3. Expression and purification of GST-OHGT(1-187). The BL21(DE3) E. coli was 
transformed with pGEX-OHGT(1-187) and GST-OHGT(1-187) expression was induced by 
IPTG treatment. Each fraction was loaded to SDS-PAGE gel. The expressed protein of 
approximately 50kDa is indicated with an unfilled triangle. 
 
 
Figure 3.4. Purification of anti-OHGT antibodies. Each eluate fraction was loaded to 
SDS-PAGE gel to confirm the abundance of IgGs. 
69 
 
3.3.3. Generating a CG3925 mutant line by CRISPR-Cas9 genome editing technology 
 To investigate whether loss of CG3925 affects Drosophila in vivo, a genome editing 
technology called Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 
system was applied. This system utilizes RNA-guided DNA endonuclease Cas9 from the type II 
bacterial adaptive immune system90,91. The Figure 3.5 shows an overview of the CRISPR-Cas9 
mediated targeted mutagenesis. In presence of guide RNA (a chimeric RNA consists of a 
sequence complementary to the genomic target site and a common sequence that is responsible 
for interaction with Cas9), Cas9 is recruited to the genomic region complementary to the guide 
RNA sequences. Cas9 induces double-stranded break three nucleotides before a specific motif 
called protospacer adjacent motif (PAM) sequence. This breakage activates an endogenous 
repair mechanism called nonhomologous end-joining. Since nonhomologous end joining often 
causes random indels insertion, leading to cause frameshift mutation or premature stop codon 
formation. 
 To utilize CRISPR-Cas9 to generate CG3925 mutant allele, a 20bp sense sequence 
within the exon 2 was chosen as the target site (Figure 3.6). Since the putative domains are 
transcribed by the exon 3 to 5, frameshift or nonsense mutation at the target sequence is 
expected to result in a strong allele or even a null allele. 
 Flies with a mutant allele were successfully recovered from the mutagenesis 
approach (Figure 3.7A-D). Molecular characterization revealed that two nucleotides before the 
predicted cleavage site by Cas9 were deleted (Figure 3.6). The loss of the nucleotides will cause 
a frameshift mutation from the exon 2, leading to express a truncated protein with only 15% of 
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the wild type protein (amino acid residues 1 to 84 of the wild type protein plus 7 amino acid 
residues caused by the frameshift (RGQSSQQ)). Since animals with this mutant allele showed 
overgrowth phenotype (see below), the gene was named ohgata (meaning "large" in Japanese; 
abbreviated as ohgt), and the generated mutant allele was named ohgtEx2. 
 Next, expression of the gene's product (Ohgata; abbrevaited as OHGT) was 
confirmed by western blotting. Total lysates of w*, homozygous ohgtEx2 (ohgtEx2/Ex2) and 
transheterozygous ohgtEx2/ohgtDf (ohgtEx2 over a Deficiency, referred to as ohgtEx2/Df) third instar 
larvae were subjected to western blotting with the two independent polyclonal antibodies 
against OHGT. OHGT protein of approximately 75kDa could neither be detected from 
ohgtEx2/Ex2 nor ohgtEx2/Df larvae (Figure 3.7E,F), suggesting that endogenous OHGT protein is 
missing in the ohgtEx2 mutant animals. It is worth noting that the putative mutant protein 
(theoretical molecular weight: 10kDa) could not be detected from the mutants (Figure 3.7F). 
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Figure 3.5. CRISPR-Cas9. A scheme represents CRISPR-Cas9-mediated genome editing. 
 
 
Figure 3.6. Targeting ohgata gene by CRISPR-Cas9. The scheme represents ohgt gene locus 
and a target site for CRISPR-Cas9-mediated targeted mutagenesis. A 20bp-long target site 
(underlined in the figure) was chosen. The vertical bar indicates the expected cleavage site. The 
protospacer adjacent motif (PAM) sequence and the premature stop codon formed by the 
mutagenesis are shown in green and red, respectively. The figure is reprinted from the Figure 
2A of Wakabayashi et al., 201665. 
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Figure 3.7. Mutagenesis screening by High resolution melt analysis. (A) The diagram 
73 
 
represents a workflow to establish a fly line with the ohgtEx2 mutant allele. (B) The table shows 
an overview of the CRISPR-Cas9 mediated mutagenesis. Concentration of plasmid solution, 
number of injected embryos, number of survivors after injection, number of eclosed flies and 
number of the positive candidate after first HRMA screening were noted. (C) The figure shows 
melting temperatures of a F1 progeny (orange curve; genotype: ohgtEx2/TM3,Sb1,Ser1,eGFP) and 
the control (gray curve: genotype: DrMio/TM3,Sb1,Ser1,eGFP). (D) The figure shows difference 
in relative fluorescence unit (RFU) between the F1 progeny and the control shown in (C). (E) 
Protein lysates from w*, homozygous ohgtEx2 (Ex2) and transheterozygous ohgtEx2/Df (Df) third 
larvae were subjected for western blotting with rabbit anti-OHGT(1-187). (F) Western blotting 
was performed identically as (E) but with guinea pig anti-OHGT(15-33). The figures are 
reprinted from the Figure 2B-E of Wakabayashi et al., 201665. 
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3.3.4. The ohgata mutants show overgrowth phenotype 
 The ohgtEx2/Ex2 animals were raised to search for associated phenotypes. The 
ohgtEx2/Ex2 animals were viable, as 79% of the mutants reached to adult stage when raised on 
standard fly food (83% of w* reached to adult stage in the same condition). During larval stage, 
amount of yeast intake was comparable to the control larvae (Figure 3.8A). Even though 30% 
showed a 12-hour delay to pupate, pupariation timing of majority of the mutant animals was 
comparable to the control animals (Figure 3.8B). Moreover, both ohgtEx2/Ex2 males and females 
were fertile, indicating that altered ohgt expression does not perturb reproduction. In all 
developmental stages, the body proportions of the mutant animals looked normal. 
 Surprisingly, the adult ohgtEx2/Ex2 flies were larger than the control flies (Figure 3.9A). 
The ohgtEx2/Ex2 male flies were significantly heavier (Figure 3.9B) and the wing area was 
significantly larger (Figure 3.9C) compared to the control. Significant increase of cell number in 
the posterior compartment of the wing was also observed (Figure 3.9D), suggesting that the 
growth phenotypes is in part due to increase in cell number. Female flies exhibited similar 
phenotypes (data not shown), suggesting that the growth phenotype is independent of gender. 
The ohgtEx2/Df animals showed a slightly enhanced phenotype, indicating that the ohgtEx2 is a 
strong allele (although probably not a null) and the phenotype is not due to off-target effects of 
the CRISPR-Cas9 mediated mutagenesis. The enlarging phenotype was already obvious in 
pupal stage, as length of the two mutants were significantly longer compared to the control 
pupae (Figure 3.9E,F). Altogether, these results suggest that impairment of ohgt results in larger 
body and organ size associated with increased cell number.  
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Figure 3.8. Feeding behavior and develop timing of the ohgt mutants are comparable to 
the control. (A) Relative yeast intake of w* and ohgtEx2/Ex2 3rd instar larvae. (B) Number of 
pupae of each genotype was counted every 12 hours. The experiment was repeated for five 
times (100 larvae for each genotype per experiment). The figures are reprinted from the Figure 
3A and C of Wakabayashi et al., 201665. 
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Figure 3.9. The ohgt mutants show overgrowth phenotype associated with increased cell 
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number. (A) w*, ohgtEx2/Ex2 and ohgtEx2/Df adult male flies. The scale bar represents 1mm. (B) 
Average weights of 3-7 days old w*, ohgtEx2/Ex2 and ohgtEx2/Df adult male flies. Flies were 
weighed in batch of 10 (n=10). (C) Average wing areas of w*, ohgtEx2/Ex2 and ohgtEx2/Df adult 
male flies (n=30). (D) Average cell number in the posterior compartment of the wing of w*, 
ohgtEx2/Ex2 and ohgtEx2/Df adult male flies (n=30). (E) w*, ohgtEx2/Ex2 and ohgtEx2/Df pupae. The 
scale bar represents 1mm. Animals whose length is the closest to the average was chosen from 
each genotype. (F) Average body length of w* (n=66), ohgtEx2 (n=80) and ohgtEx2/Df (n=73) 
pupae. The figures are reprinted from the Figure 3B, D-H of Wakabayashi et al., 201665. 
  
78 
 
3.3.5. The gene's product OHGT is expressed in the larval fat body 
 Body size and its proportion are determined by genetic factors, as well as 
environmental factors during development such as nutrients, temperature, population density 
and presence of pathogens. Metazoans utilize the conserved insulin/insulin-like growth factor 
signaling (IIS) pathway to couple body size with extrinsic cues92. 
 Genetic studies using Drosophila made significant contributions to understand a 
genetic program growth in multicellular organism including insulin-like signaling (ILS)93,94. 
Drosophila genome contains eight genes encoding insulin-like peptides (DILPs) that function as 
ligands of a common Insulin-like receptor (dInR). Activation of dInR by DILPs initiates a signal 
cascade that resembles the mammalian IIS pathway, consists of components such as 
phosphoinositide 3-kinase (dPI3K), serine-threonine kinase dAkt, and forkhead transcription 
factor dFOXO93,94. Genetic defects or manipulation of the pathway's component results in 
altered cell size and cell number, leading to altered body and organ size74,95–97. 
 The insulin-producing cells (IPCs) are the major production and secretion sites of 
DILPs. The IPCs are the symmetric clusters of seven neurosecretory cells located in each brain 
hemispheres96,98. The IPCs produce and secrete at least four DILPs (DILP1, 2, 3 and 5), and 
ablation of these cells results in small adults, just like mutants of genes encoding ILS 
components98. 
 The fat body, the functional analog of mammalian liver and adipose tissue, is another 
organ that plays versatile roles in systemic ILS regulation94. The larval fat body produces DILP6, 
the Drosophila homolog of mammalian IGF1, to regulate post-feeding growth99,100. Also the 
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organ was identified as the primary nutrient sensor, which produces and secretes numerous 
humoral factors into haemolymph (circulating fluid in Drosophila) upon changes in nutrient 
conditions101,102. Fat body-derived factors with variety of functions in the context of ILS 
regulation have been described75,77,99,100,103–107. 
 To confirm whether the product of ohgt (Ohgata; OHGT) is expressed in the major 
growth regulating sites, immunohistochemical analysis was performed using the OHGT-specific 
antibody. First the IPCs were visualized using an IPCs-specific Gal4 driver line (dilp2-Gal4) 
and a line that expresses GFP under the control of the upstream activating sequence (UAS) 
(UAS-GFP.nls). OHGT was not detected from the GFP positive cells (Figure 3.10A,B), 
suggesting that it is not expressed in the larval IPCs. On the other hand, OHGT was prominently 
expressed in the fat body (Figure 3.10C,D). The signal observed in the wildtypic fat body was 
strongly reduced in those of the ohgtEx2/Df (Figure 3.10E,F) and ohgt RNAi-induced clones 
(Figure 3.11A-F). These results indicate that endogenous OHGT protein is indeed localized in 
fat body cells. Of note, OHGT was almost exclusively present in the nucleus (Figure 3.10C,D), 
which is consistent with results from subcellular fractionation of S2 cells (Figure 3.12) and 
bioinformatic prediction algorithms for proteins subcellular localization including the Reinhardt 
NCNN algorithm and NucPred (data not shown). The subcellular location of OHGT was not 
dramatically changed either in nutrient scarce condition or in other developmental timings (data 
not shown). These results indicate that OHGT is a nuclear protein in fat body cells. 
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Figure 3.10. OHGT is expressed in larval fat body cells but not in the IPCs. (A,B) OHGT 
was co-immunostained along with GFP expressed in the IPCs of dilp2>GFP third instar larvae. 
(C,D) OHGT was co-immunostained along with a plasma membrane marker α-spectrin in the 
fat body of w* third instar larvae. (E,F) OHGT was co-immunostained along α-spectrin in the 
fat body of ohgtEx2/Df third instar larvae. All scale bars represent 50μm. Rabbit 
anti-OHGT(1-187) was used in all experiments. The figures are reprinted from the Figure 4A-F 
of Wakabayashi et al., 201665. 
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Figure 3.11. Expression of OHGT is reduced upon ohgt RNAi induction. (A,B) 
Co-immunostiaining of OHGT and GFP after clonal ohgt RNAi induction in fat body cells of 
third instar larvae. GFP-positive cells (pointed by the arrows in the panel A) are ohgt RNAi 
induced clonal cells and GFP-negative cells are wild type clonal cells. The scale bar represents 
50μm. Rabbit anti-OHGT(1-187) was used in this experiment. (C-F) Normalized staining 
intensities of OHGT in whole cell (C), the cytoplasm (D), the nucleus (E) as well as nuclear to 
cytoplasm ratio of wild type clonal cells (n=34) and ohgt RNAi induced clonal cells (n=17). 
Error bars indicate S.E.M. * indicates p<0.05 and ** indicates p<0.01, respectively. P values 
were calculated by Man-Whitney U test. The figures are reprinted from the Figure 4G-L of 
Wakabayashi et al., 201665. 
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Figure 3.12. Subcellular fractionation of S2 cells. S2 cells were fractionated into the 
cytoplasmic and the nuclear fractions. Equal amounts of proteins from the cytoplasmic (C) and 
the nuclear (N) fractions were subjected to western blotting with antibodies against the indicated 
proteins. 
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3.3.6. Loss of ohgata in the fat body is sufficient to phenocopy the growth phenotype of the 
mutants 
To address whether OHGT in the fat body is involved in growth regulation, males of 
an ohgt RNAi line (v40486 from the Vienna Drosophila Resource center; referred to as 
UAS-ohgtRNAiv40486) were crossed with virgin females of a fat body Gal4 driver line (Cg-Gal4) to 
obtain progenies with reduced ohgt expression in the fat body (referred to as Cg>ohgtRNAiv40486). 
First, ohgt transcript level in the Cg>ohgtRNAiv40486 third instar larvae were quantified by 
qRT-PCR. In the fat body, ohgt transcript was reduced by about 80%, whereas it was not altered 
in the carcass (larval bodies after fat body removal) (Figure 3.13). This result indicates that ohgt 
expression is strongly reduced only in the fat body of Cg>ohgtRNAiv40486 larvae. 
 Next, Cg>ohgtRNAiv40486 animals were raised along with the control animals (Cg>w*). 
As expected, Cg>ohgtRNAiv40486 animals showed overgrowth phenotype similar to those of the 
ohgt mutants. They showed significant increase in pupal length (Figure 3.14A,B), as well as in 
adult weight (Figure3.14D) and in wing area (Figure3.14E). Increase of wing area suggests that 
OHGT in the fat body regulates size of other organs non-cell autonomously to some extent. 
Using another ohgt RNAi line (NIG3925R-3 from National Institute of Genetics; referred to as 
UAS-ohgtRNAiNIG3) or a different fat body Gal4 driver line (FB-gal4) resulted in larger pupae 
(Figure 3.14B), suggesting that the observed growth phenotypes are in part due to the reduction 
of ohgt in the fat body. These results point out an organ-specific function of OHGT to regulate 
organismal growth. 
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Figure 3.13. ohgt is reduced upon RNAi induction in the fat body. Transcript level of ohgt in 
the fat body and the carcass of 72h AED Cg>w* and Cg>ohgtRNAiv40486 larvae (n=4). The figures 
are reprinted from the Figure 5A of Wakabayashi et al., 201665. 
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Figure 3.14. Cg>ohgtRNAiv40486 animals phenocopy the ohgt mutant phenotypes. (A) Cg>w* 
and Cg>ohgtRNAiv40486 pupae. An animal whose body length is closest to the average was used 
for image acquisition. The scale bar represents 1mm. (B) Average body length of Cg>w* (n=48) 
versus Cg>ohgtRNAiv40486 (n=66); Cg>w* (n=40) versus Cg>ohgtRNAiNIG3 (n=48); FB>w* (n=48) 
versus FB>ohgtRNAiv40486 (n=52). (C) Cg>w* and Cg>ohgtRNAiv40486 adult male flies. The scale 
bar represents 1mm. (D) Average weight of Cg>w* and Cg>ohgtRNAiv40486 adult male flies (n=8). 
(E) Average wing area of Cg>w* and Cg>ohgtRNAiv40486 adult male flies (n=20). The figures are 
reprinted from the Figure 5B-F of Wakabayashi et al., 201665. 
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3.3.7. Loss of ohgata leads to elevated insulin-like signaling 
The observed phenotypes of ohgtEx2 mutants were reminiscent to animals associated 
with high ILS activity75,95,104. In order to investigate whether altered loss of ohgt is associated 
with altered ILS activity, expression level of phosphorylated dAkt was analyzed. Since Akt gets 
phosphorylated under high ILS activity108 (Figure 3.15), level of phosphorylated Akt is an 
experimental readout for activity of the signaling pathway. Total protein lysate of ohgtEx2/Ex2 
third instar larvae was subjected to western blotting with phsopho-Akt specific antibody and 
found that phospho-dAkt level in the ohgtEx2/Ex2 larvae was indeed higher than in control larvae 
(Figure 3.16A), suggesting that ILS is elevated in the ohgt mutants. The major role of Akt is to 
phosphorylate transcription factor FOXO, resulting in its retention in the cytoplasm109. 
Downregulation of ILS allows dFOXO to shuttle into the nucleus, promoting expression of its 
target genes97 (Figure 3.15). To confirm dFOXO's activity in the ohgtEx2/Ex2 mutants, expression 
levels of two dFOXO target genes, d4EBP and dInR, were quantified by qRT-PCR. Consistent 
with increased phospho-dAkt level, the two target genes were downregulated in ohgtEx2/Ex2 
mutant larvae compared to the control animals (Figure 3.16B). Increased level of phospho-dAkt 
and downregulated d4EBP (but not dInR) were also observed upon ohgt inhibition in the fat 
body (Figure 3.16C,D). Along with the previous phenotypic data, these results lead to a 
conclusion that OHGT in the fat body negatively regulates organismal growth via ILS. 
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Figure 3.15. Drosophila insulin-like signaling. The diagram shows a simplified signal cascade 
of Drosophila ILS. Circulating DILPs interacts with a common dInR to stimulate downstream 
components including dPI3K, dAkt and dFOXO. Activated dInR also stimulates MAPK 
pathway in distinct manner. 
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Figure 3.16. Loss of ohgt is associated with elevated ILS. (A) Total protein lysates of w* and 
ohgtEx2/Ex2 72h AED larvae were subjected to western blotting with phospho-Akt specific 
antibody (the experiment was performed more than three times). (B) Transcript levels of two 
dFOXO target genes, d4EBP and dInR, in w* and ohgtEx2 72h AED larvae (n=4). (C) Protein 
lysates of Cg>w* and Cg>ohgtRNAiv40486 72h AED larval carcasses were subjected to western 
blotting with phospho-Akt specific antibody (the experiment was performed in triplicate). (D) 
Transcript levels of d4EBP and dInR, in Cg>w* and Cg>ohgtRNAiv40486 72h AED larval carcasses 
(n=4). The figures are modified from the Figure 6A-D of Wakabayashi et al., 201665. 
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3.3.8. Loss of ohgata alters expression of genes encoding DILPs' cofactors 
 The fat body is an endocrine organ that produces and secretes humoral proteins in 
response to changes in nutrient conditions101,102 (Figure 3.17). Among those, there are some 
proteins that interact with DILPs after their release into haemolymph. Acid labile subunit 
(dALS)75 and Imaginal morphogenesis protein-Late 2 (IMP-L2)104 are the two 
DILPs-interacting proteins that have been described in Drosophila. In circulation, dALS and 
IMP-L2 forms a heterotrimeric complex with DILP2 or DILP5 to suppress them from 
interacting with peripheral dInR75,104. During larval stage, dALS is produced in the IPCs and in 
the fat body, thereby antagonizing DILPs in growth control as well as carbohydrates and lipids 
metabolism75. IMP-L2 is already present in the cellular blastoderm stage and can be observed in 
several cell types throughout development110. It was identified as a protein counteracting 
hyperplasia induced by dInR overexpression, and its loss results in larger body size and 
enhanced vulnerability to starvation104. Another studies demonstrated that IMP-L2 is secreted 
from malignant tumors to reduce ILS in proximal tissues, resulting in loss of the organs known 
as organ-wasting76,111. Thus, these two proteins are proposed as circulating DILPs antagonists in 
Drosophila. 
 To investigate whether reduction of ohgt affects expression levels of genes encoding 
the DILPs cofactors, qRT-PCR was performed using cDNAs synthesized from total ohgtEx2/Ex2 
third instar larvae and cDNAs synthesized from the fat body of Cg>ohgtRNAiv40486 third instar 
larvae. Intriguingly, Imp-L2 was reduced only in the total fraction, whereas dALS was reduced 
in both total and the fat body specific fractions (Figure 3.18A,B). unpaired 2 (upd2), one of  
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the genes encoding DILPs secretion promoting factors, was not altered in both genetic 
conditions (Figure 3.18A,B). These results are consistent with the previous study showing that 
the fat body is the major production site of dALS, and its fat body-specific knock down leads to 
increased final body weight75. 
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Figure 3.17. The larval fat body coordinates nutrient abundance and growth. The scheme 
showing a part of humoral relay mechanisms for systemic ILS regulation. The fat body 
produces and secretes both DILPs secretion-promoting factors (ex. UPD2) and DILPs inhibitory 
cofactors (dALS and IMP-L2) in response to changes in nutrient condition. 
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Figure 3.18. Genes encoding DILPs cofactor were downregulated under genetic inhibition 
of ohgt. (A) Transcript levels of genes encoding Acid labile subunit (dALS), 
Imaginal-morphogenesis Late 2 (Imp-L2), and unpaired 2 (upd2) in w* and ohgtEx2 72hAED 
larvae (n=4). (B) Transcript levels of dALS, Imp-L2, and upd2 in Cg>w* and Cg>ohgtRNAiv40486 
72h AED larval carcasses (n=4). The figures are modified from the Figure 6E,F of Wakabayashi 
et al., 201665. 
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3.3.9. OHGT interacts with Piccolo, the Drosophila ortholog of DDB1 
 Previous studies have demonstrated that vertebrate CRBN family members is a 
substrate receptor of the CRL4 complex to regulate stability and turnover of substrate proteins 
via ubiquitination4. Crystallographic studies have identified that the structural feature of the 
DDB1-binding motif is conserved among vertebrates1,2. 
 The Drosophila homolog of DDB1 has been identified by sequence comparison112. 
The gene encoding the protein was later determined to be allelic to a previously defined locus 
called piccolo (pic)113. Previous genetic studies revealed its putative roles in development and 
genome stability maintenance113–115. The pic gene consists of seven exons (Figure 3.19A), which 
encodes a protein consisting of 1140 amino acid residues with a theoretical molecular weight of 
126kDa. The protein (PIC) shows 61% sequence identity with human DDB1 throughout the 
sequence, and three domains (WD repeat β-propeller A, B and C) are well conserved (Figure 
3.19B). 
 To investigate whether OHGT interacts with PIC in a manner similar to the human 
CRBN-DDB1 interaction, a 3D structure model for the OHGT-PIC complex was created using 
the crystallization data (PDB 4TZ4) as a template (Figure 3.20A,B). The OHGT-PIC complex 
model showed that the interaction interface may be similar to that of the human complex 
(Figure 3.20C,D). 
 Next, biochemical experiments were performed to confirm the interaction between 
OHGT and PIC. A commercial polyclonal antibody against human DDB1 could detect a protein 
of the expected size from total S2 lysate (Figure 3.21A). 
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 Using this antibody, co-immunoprecipitation experiments in Schneider 2 (S2) tissue 
cell culture were performed. PIC was detected from both HA-OHGT-containing 
immunocomplex (Figure 3.21B) and endogenous OHGT-containing immunocomplex (Figure 
3.21C), suggesting that OHGT and PIC indeed form a complex in S2 cells (Figure 3.21C). 
 Mammalian CRBN and other CRL4 components are known to undergo 
autoubiquitination under certain conditions, including absence of specific substrate proteins or 
the presence of MG1324,116,117. Therefore, ubiquitination assay was performed by purifying 
endogenous OHGT in the presence of MG132. Endogenous OHGT was indeed 
polyubiquitinated after overnight MG132 treatment (Figure 3.21D), similar to human CRBN 
(chapter 2 of this thesis). These results altogether suggest that OHGT may also be a substrate 
receptor of the CRL4 in Drosophila. Unfortunately, genetic interaction between ohgt and genes 
encoding other CRL4 components could not be proved because both pic and dCullin4 RNAi 
induction in the fat body using the Cg-Gal4 resulted in complete lethality during larval stage 
(data not shown). Also, attempts to purify endogenous or tagged-OHGT from larval lysates 
were unsuccessful (data not shown). Therefore, biochemical analysis using S2 cells could not be 
extended towards functional experiments with putative interaction partners in vivo. 
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Figure 3.19. The piccolo gene encodes the Drosophila homolog of human DDB1. (A) A 
scheme representing pic gene locus. Exons and untranslated regions are indicated as filled boxes 
(light gray and dark gray, respectively). The scale bar represents 1kbp. (B) Schemes 
representing human DDB1 and Drosophila PIC. Evolutionary conserved WD repeat β-propeller 
A, B and C domains (BPA, BPB, BPC) are indicated as filled boxes (green). Amino acid 
identities of the corresponding regions are noted. 
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Figure 3.20. The 3D model of OHGT-PIC complex. (A) The 3D model of OHGT-PIC 
complex was created and aligned to respective positions in 4TZ4. (B) The structure of the 
human CRBN-DDB1 complex (PDB 4TZ4)2. (C,D) The close-up views of the 
OHGT-PIC/CRBN-DDB1 interaction interfaces. (C',D') Amino acid side chains of 
OHGT/CRBN that point towards the PIC/DDB1 interface are shown in red. The figures are 
modified from the Figure 7A-D of Wakabayashi et al., 201665. 3D modeling of OHGT-PIC 
complex was conducted in collaboration with A. Voelzmann. 
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Figure 3.21. OHGT binds to PIC and may be a substrate receptor of the Drosophila CRL4 
complex. (A) Total S2 cells lysate was subjected to western blotting with human DDB1-specific 
antibody. Total Hela cells lysate was used as the positive control. (B) S2 cells were 
co-transfected with pUASTattB-HA-OHGT and pAct-Gal4, and protein complex containing 
HA-OHGT was immunopurified using HA-specific antibody. Total lysates (Input) and 
immunoprecipitates (IP) were subjected to western blotting with antibodies to the indicated 
proteins (for detecting OHGT, guinea pig anti-OHGT(15-33) was used). (C) Protein complex 
containing endogenous OHGT was immunopurified using rabbit anti-OHGT(1-187). Total 
lysates (Input) and immunoprecipitates (IP) were subjected to western blotting with antibodies 
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to the indicated proteins (for detecting OHGT, guinea pig anti-OHGT(15-33) was used). (D) S2 
cells were treated with MG132, subsequently endogenous OHGT was immunopurified using 
using rabbit anti-OHGT(1-187). Total lysates (Input) and immunoprecipitates (IP) were 
subjected to western blotting with antibodies to the indicated proteins (for detecting OHGT, 
guinea pig anti-OHGT(15-33) was used). The figures are reprinted from the Figure 7E-G of 
Wakabayashi et al., 201665. 
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3.4. Discussion 
 Growth regulation in multicellular organisms is controlled by paracrine and 
endocrine mechanisms, which coordinate organ size with extrinsic cues to determine size and 
proportions of the body. In particular, nutrient abundance during growth period has a strong 
influence on organismal growth, and the genetic programs underlying growth must be able to 
adapt their growth and metabolic programs to altered nutrient conditions. The conserved IIS/ILS 
cascade is the key growth regulatory pathway. Circulating ligands including insulin, IGF or 
insulin-like peptides initiates the signal cascade regulating metabolism, cell proliferation and 
cell growth in peripheral organs. Utilization of this humoral system enables organisms to control 
growth in orchestrated manner. 
 The present work unveiled that OHGT is a novel growth regulator in Drosophila. 
OHGT in the fat body negatively regulates ILS. In the ohgt mutants generated by CRISPR-Cas9 
mediated targeted mutagenesis, increased level of phospho-dAkt, reduced level of dFOXO 
target genes and reduced level of genes encoding DILPs' cofactors were associated with 
overgrowth phenotype. To the author's knowledge, this is the first evidence arguing that a 
CRBN family member regulates growth via IIS/ILS. 
 In vertebrates, IGFs are the major player to regulate growth. IGF-1 is synthesized in 
the liver and they accumulates in body fluids as a heterotrimeric complex with ALS and 
IGFBP3/5118. Formation of the complex improves stability of IGF-1, thereby promoting its 
half-life in circulation118. A similar ternary complex have been identified in Drosophila, as 
DILP2 forms a complex with dALS and IMP-L2 in haemolymph75. Knockdown of dALS in the 
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fat body increases final body weight75, whereas overexpression of Imp-L2 ameliorates 
hyperplasia caused by dInR misexpression104. 
 Downregulation of dALS and Imp-L2 was associated with the ohgt mutants. This 
result implicates that OHGT in the fat body may play a role in a feedback loop (Figure 3.21). In 
physiological condition, circulating DILPs promotes ILS in periphery including fat body cells. 
The ILS may alter OHGT's functions, which in turn activates transcription of some genes 
including dALS (and also Imp-L2 to a minor extent). The fat body subsequently releases dALS 
into haemolymph, suppressing DILPs activity. In the absence of functional OHGT, on the other 
hand, fat body cells may not be able to properly activate transcription of dALS. Insufficient 
amount of dALS increases active DILPs in circulation, promoting overgrowth in periphery. Of 
note, upregulation of dilp6, a gene encoding the functional homolog of vertebrate IGF-1, was 
also observed (data not shown). Previous studies have reported that dilp6 deletion mutants show 
a growth defect phenotype resulting in smaller body size99,100. Elevation of dilp6 in the ohgt 
mutants may also contribute to enhance the overgrowth phenotype. 
 Intriguingly, dALS was reduced in both total and fat body specific fractions, whereas 
Imp-L2 was only reduced in total fraction but not in fat body specific fraction. These results 
suggest that OHGT in other organs may be responsible for the Imp-L2 downregulation. Larval 
muscle was previously shown to non-autonomously regulate ILS via producing IMP-L2119, 
therefore OHGT in muscle might function in similar manner with that in the fat body. 
 Vertebrate CRBN is a substrate receptor of the CRL4 complex that mediates 
ubiquitin-dependent degradation of specific substrates4
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CRL4CRBN complex regulates transcription by two distinct mechanisms: by directly targeting 
and degrading transcription factors1,8,10 and by targeting histones at a specific regulatory 
region13. Through an unbiased biochemical screen, a homeobox protein MEIS2 was identified 
as an endogenous substrate of the CRL4CRBN complex1. Also, in the presence of lenalidomide, 
the complex targets two lymphoid-specific transcription factors Ikaros and Aiolos for 
polyubiquitination and degradation8,10. A recent publication demonstrated that in mammalian T 
cells, CRBN directly binds to a regulatory region of Kcna3 gene13, in turn recruits other CRL4 
components and a histone methyltransferase EZH1 to promote histone modification, resulting in 
altered expression of the gene13. 
 All the components of the CRL4 complex are conserved in Drosophila113. Functional 
null mutations of dCullin4 or pic leads to growth arrest during larval stage and are lethal113. 
Consistent with the conservation of the CRL4 complex, the modeling of the OHGT-PIC 
complex according to the human CRBN-DDB1 crystallization data revealed that the interaction 
interface between the Drosophila proteins may share structural properties with the human 
proteins. This modeling was further supported with co-immunoprecipitation studies in S2 tissue 
culture cells in the present work. Unfortunately, the presence of the CRL4OHGT in vivo could not 
be confirmed either genetically or biochemically in this work. Therefore, further investigations 
are required to address whether the CRL4OHGT complex is present and regulates growth in vivo. 
 If CRL4OHGT is indeed present, whether the complex plays a role in growth regulation 
via interacting with unknown proteins is an interesting question left unanswered. One potential 
substrate could be dFOXO, the major downstream transcription factor of ILS. Of note, several 
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studies have demonstrated that mammalian FOXO proteins and another Cullin family member, 
the Skp1-Cullin1-Skp2 complex, negatively regulates their functions to each other. The 
Skp1-Cullin1-Skp2 complex targets phosphorylated FOXO1 for ubiquitination and subsequent 
degradation under high IIS activity120. Another FOXO protein, FOXO3A was shown to directly 
binds to Skp2, negatively regulating the complex formation and its E3 ubiquitin ligase 
activity121. Thus similar functional regulatory mechanism between the CRL4OHGT and dFOXO 
could exist in Drosophila. 
 The transheterozygous ohgtEx2 over deficiency mutants showed slightly stronger 
phenotypes compared to the homozygous ohgtEx2 mutants in body and organ size quantification 
(Figure 3.9), indicating that the ohgtEx2 allele may not be a null allele. This mutant allele is 
expected to express a mutant protein consists of amino acids 1 to 84 of the endogenous OHGT 
protein plus extra seven amino acid residues induced by a frameshift mutation. The only 
potential sequence motif found in this region through in silico analyses was a non-covalent 
SUMO-interacting motif (amino acids 34-38; VDVIE) (Figure 3.1D). As roles of non-covalent 
SUMO-interaction in E3 ubiquitin ligase activity regulation have been identified in other 
species122–124, the potential SUMO-interacting motif in the N-terminal region could have 
biological significance. 
 One unique aspect of CRBN family members is that certain class of small molecules 
can modulate their functions. Thalidomide and its analogs was shown to modulate interaction 
between CRBN and a number of substrates1,6,8,10,11,36. CRBN homologs across the animal and 
plant kingdoms exhibit 100% sequence conservation in three tryptophan residues that form a 
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hydrophobic pocket occupied by the small molecules, implicating that endogenous modulators 
of these proteins may exist2. Future investigations will be required to elucidate whether 
functions of OHGT can be regulated by such still unidentified modulators. 
 
104 
 
 
Figure 3.22. A hypothetical model of the overgrowth phenotype. (Top) In normal condition, 
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dInR initiates ILS that is transduced to nuclear OHGT, which in turn activates transcription of 
genes including dALS by unknown mechanism. The fat body secretes dALS into circulation, 
suppressing activity of DILPs. (Bottom) When functional OHGT is missing or reduced, 
transcription of dALS is not properly activated in response to ILS. Reduction of secreted dALS 
enhances activity of circulating DILPs, promoting ILS in peripheral tissues. 
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Chapter 4. Conclusion and future prospect 
 
 In this thesis, functions of human CRBN and OHGT, its Drosophila ortholog, was 
described. In the chapter 2, cytoprotective function of CRBN against misfolded proteins 
accumulation induced by proteasomal dysfunction was described. In the chapter 3, OHGT was 
demonstrated as a novel regulator of ILS-mediated growth of Drosophila. These studies provide 
insights for pleiotropic functions of CRBN family members. 
 The genetic clinical studies have suggested that altered expression and/or functions 
of CRBN are linked to onset of IDs9,12. Although expression of CRBN family members have 
been confirmed in the vertebrate central nervous systems4,125, functions of their products still 
remain unknown. Drosophila is a suitable model to study functions of CRBN family member in 
the central nervous system, with accessibility to numerous genetic tools including a collection 
of Gal4 driver lines that enables expression of exogenous genes in small subsets of neurons126–
128. 
 In addition to growth and metabolic regulation, ILS is linked to other biological 
phenomenon. Of note, roles of Drosophila ILS have been well described in the context of life 
span determination and the innate immune response. 
 A great amount of literatures proved that altered IIS/ILS influences aging in 
eumetazoans129,130. In Drosophila, various genetic conditions that mimic systemic or 
tissue-specific reduction of ILS, including mutation of the pathway component131, ablation of 
the IPCs132 and overexpressing dFOXO133–137, have been reported to prolong lifespan.  
 Combating pathogens is an energy demanding process; hence it is reasonable that 
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ILS is linked to immune response mechanisms. Studies identified that elevated innate immune 
response by bacterial infection or genetic manipulation can alter systemic ILS, leading to 
changes in energy storage138,139. Furthermore, a direct role for dFOXO in the innate immune 
response has been described. Becker and colleagues showed that dFOXO upregulates genes 
encoding antimicrobial peptides independently from the canonical innate immunity pathways140. 
 Along with the physiological processes, Drosophila ILS has been implicated in some 
pathological conditions including cancer. Recently, two groups independently identified that the 
tumor cells in adult Drosophila secrete IMP-L2 to downregulate ILS in periphery, hence 
inducing robust wasting phenotypes that resemble cachexia condition observed in human cancer 
patients76,111. 
 Whether OHGT is involved in these ILS-related biological phenomenon and/or 
pathological conditions, and whether these functions are evolutionary conserved, in particular in 
mammals, are the intriguing questions that require further investigations to address in the future. 
 Finally, Drosophila may be a useful model for discovery of therapeutic drugs 
targeting CRBN. In the last decade, Drosophila became increasingly popular as an in vivo 
cancer model, mainly due to high conservation of tumorigenesis-relevant signal pathways 
between human and Drosophila, and its powerful genetic tools141,142. Recently, it has been 
considered that Drosophila may be a suitable alternative to tissue culture cells for selecting 
potential antitumor compounds before conducting rodent assays143. 
 In the past few years, CRBN has gained attention as the primary target of IMiDs for 
therapeutic effects against hematological cancers8,10. Several groups have succeeded to generate 
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novel thalidomide derivatives with functional moieties that promote CRL4CRBN to target specific 
substrates for ubiquitination and degradation36,144,145. Because the human CRBN-DDB1 
complex and the Drosophila counterpart share structural similarity within the interaction 
interface as shown in this work, human CRBN therefore may function as a substrate receptor of 
the Drosophila CRL4 complex in vivo. Humanized Drosophila expressing human CRBN may 
be an excellent screening model for discovering novel thalidomide analogs with therapeutic 
effects. 
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